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Foreword 
The Scientific Committee for Animal Nutrition (SCAN) was created by 
Commission Decision 76/791/EEC of 24 September 1976^1^ in order to 
provide the Commission with informed opinions on scientific and technical 
matters related to animal nutrition and related aspects. 
The members of the Scientific Committee for Animal Nutrition are 
independent and highly qualified scientists in the relevant fields of 
veterinary and human medicine, animal nutrition, food and feed sciences 
and environmental protection. The president is elected by its members and 
the secretariat is provided by the Commission. 
The SCAN expresses its opinions on answers to specific questions from the 
Commission. These are published by the Commission^2). The opinions 
expressed reflect the present state of knowledge concerning aspects of 
animal health and nutrition and other related matters in regard to 
Community legislation, and in particular: 
Council Directive 70/524/EEC of 23 November 1970 concerning additives 
in feedingstuffs^3) as ammended by Council Directive 84/587/EEC of 
29 November 1984<4), 
Council Directive 87/153/EEC of 16 February 1987 fixing guidelines 
for the assessment of additives in animal nutri tion^5), 
Council Directive 82/471/EEC of 30 June 1982 concerning certain 
products used in animal nutrition^6), 
(1) O.J. No. L279 (09.10.1976) p. 35. 
(2) See cumulative index in pages 87-95 of this report. 
(3) O.J. No. L 270 (14.12.1970), p. 1. 
(4) O.J. No. L 319 (08.12.1984). p. 13. 
(5) O.J. No. L 64 (07.03.1987), p. 19. 
(6) O.J. No. L 213 (21.07.1982). p. 27. 
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Council Directive 83/228/EEC of 18 April 1983 on the fixing of 
guidelines for the assessment of certain products used in animal 
nutr it ion^7), 
Council Directive 74/63/EEC of 17 December 1973^8) on the fixing of 
maximum permitted levels for undesirable substances and products in 
feedingstuffs as amended by Council Directive 86/354/CEEÍ9). 
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1st series 
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3rd ser ies 
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5th ser ies 
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8th ser ies (1992) (in preparat ion) 
(7) O.J. No. L 126 (13.05.1983). p. 23. 
(8) O.J. No. L 38 (11.02.1974). p. 31. 
(9) O.J. No. L 212 (02.08.1986), p. 27. 
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Report of the Scientific Committee for Animal Nutrition on the use of 
lasalocid sodium in feedingstuffs for finishing cattle. (Opinion 
expressed : 27 July 1990). 
Terms of reference (February 1984) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Has the use of lasalocid sodium under the conditions proposed for 
feedingstuffs for finishing cattle significant effects on animal 
growth? 
2. Does this use result in the presence of residues in tissues and 
organs of the animal? If so, what is the qualitative and quantitative 
composition of these residues? Could these residues be harmful to 
the consumer? 
3. Could this use affect the development of resistance in bacteria? 
4. Could the excreted products, derived from the additive, be 
prejudicial to the environment? 
5. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
Background 
In accordance with the provisions of Council Directive 70/524/EEC of 
23 November 1970 concerning additives in feedingstuffs^1), as last 
amended by the forty fourth Commission Directive of 29.11.1983(2), the 
(1) O.J. N· L 270. 14.12.1970. p. 1 
(2) O.J. N-L350. 13.12.1983. p.17. 
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use of lasalocid sodium is authorized at Community level under the 
conditions set out as follows in Annex 1, Section D, of the Directive. 
Species of animal : chickens for fattening. 
Minimum and maximum content in complete feedingstuffs: 75­125 mg/kg. 
Other provisions: use prohibited for at least five days before slaughter. 
The Scientific Committee for Animal Nutrition expressed a favourable 
opinion on this use in its report of 14 December 1982. 
Opinion of the Committee 
The file submitted to the Committee related to BOVATEC^*), a premi χ 
containing 15% lasalocid sodium. 
1. Thirty­two trials with lasalocid sodium were conducted between 1978 
and 1987 in several countries on some 2500 cattle of various breeds 
maintained under different husbandry conditions. They showed that 
lasalocid sodium, at concentrations between 10 mg and 35 mg/kg of 
complete feedingstuff, favourably influenced growth and improved the 
feed conversion ratio. The highest concentration employed did not 
achieve statistically significant greater effects than lower 
concentrât ions. 
Evaluation of the efficacy in relation to the energy density of the 
animal diet showed the existence of an inverse relationship between 
feed intake and energy value of the ration. However, the addition of 
lasalocid sodium to low energy rations tended to increase body weight 
gain without concomitant effect on feed intake. This phenomenon has 
been observed also with other ionophore antibiotics. Overall it could 
be shown that lasalocid sodium, at a concentration of 35 mg/kg of 
complete feedingstuff, improved feed efficiency from 7% to 15% for 
low energy rations and from 3% to 5% for high energy rations. Grazing 
trials using lasalocid sodium at doses ranging from 100­300 
mg/animal/day showed a greater improvement in daily body weight gain 
(the only parameter which can be measured in these trials) than feed­
lot trials (in these trials 3 parameters can be measured: feed 
consumpt ion, feed conversion, and mean daily body weight gain). 
(·) Registered trade nome of Hoffmann-LaRoche 
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Lasalocid sodium also reduced the incidence of meteor ism (bloat) in 
cattle kept on dried leguminous feed. 
Lasalocid sodium at concentrations of 50 mg/kg feedingstuff, altered 
the volatile fatty acid composition of the rumen contents by 
increasing significantly the molar proportion of propionic acid, 
though even concentrations as high as 176 mg/kg feedingstuff did not 
increase the total volatile fatty acid concentration in rumen. 
Although the proposed levels of use ranging from 10-35 mg/kg of 
complete feedingstuff appear to be efficacious, there is a need to 
avoid the incorrect use in ruminating cattle of complementary feed 
containing lasaloid sodium. It would therefore be appropriate to fix 
a maximum daily dose for each animal according to its body weight 
because feed consumption during rumination does not increase 
proportionally with the body weight. The maximum dose of lasalocid 
sodium in the daily ration should not exceed 50 mg (constant value) 
plus 55 mg/100 kg body weight (variable value). The table below sets 
out the appropriate quantities. 
Live weight Mean daily feed lasalocid Na/head/day Equivalent dose in 
consumption (50mg+55mg/100kg b.w.) complete feed 
(kg) (kg) (mg) (mg/kg) 
100 3.4 115 34 
150 4.4 132.5 30 
200 5.6 160 29 
250 6.7 187.5 28 
300 7.6 215 28 
350 8.3 242.5 29 
400 9.0 270 30 
450 9.6 297.5 31 
500 10.4 325 31 
550 10.5 352.5 34 
600 10.9 380 35 
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The use of lasalocid sodium in feedingstuffs for cattle did not 
affect carcase quality. Organoleptic tests carried out on beef meat 
showed no difference between samples from control animals and animals 
which had received 165 mg lasalocid sodium/kg feedingstuff. No 
adverse effects due to lasalocid sodium administration were noted in 
target animals such as chickens, laying hens, turkeys, heifers, cows 
and horses at doses up to 0.6 mg/kg body weight, equivalent to 
35 mg/kg of complete feedingstuff. The tolerance of rabbits to 
repeated administration of lasalocid sodium has not been determined. 
2. The oral acute toxicity of lasalocid sodium was about 100 mg/kg body 
weight in rats and about 150 mg/kg body weight in mice. The substance 
was not irritating to the skin and eyes of rabbits. A sensitization 
test in guinea-pigs was negative. 
Mutagenicity studies in prokaryotic and eukaryotic organisms as well 
as in vitro assays for several genetic endpoints were all negative. 
Long-term studies in mice, rats and dogs showed no evidence of any 
carcinogenicity. The increased incidence of lymphosarcoma observed in 
the mouse study was within the range noted in historical controls. It 
was therefore not considered to be indicative of any carcinogenic 
potential. At high dose levels changes were noted in some 
haematological and el i n ico-chemicaI parameters and in some organ 
weights. The no-observable effect level (NOEL) in the rat was 
0.5 mg/kg body weight. The highest dose of 6 mg/kg body weight in a 
three-generation-reproduction study in rats induced weight-loss-
related effects on male and female fertility but no evidence of 
teratogenicity. The NOEL in this study was 1.8 mg/kg body weight. The 
ADI for man was established at 0.005 mg/kg body weight based on the 
NOEL in a long-term study in rats. Lasalocid sodium had no adverse 
effects in target and non-target animal species at doses up to 
35 mg/kg feed. 
The metabolic fate of lasalocid sodium was studied in steers using 
14C-labelled lasalocid. Single dose administration produced very 
low blood radioactivity levels, 89% of the administered radioactivity 
being recovered in the faeces and 0.18% in the urine after 24 hours. 
Some 80% of the faecal radioactivity was extractable, divided into 
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54% unchanged lasalocid and 26% other products, representing at least 
5 metabolites. None of the metabolites was present at more than 4.5%. 
Lasalocid is partly absorbed and then excreted in the bile either as 
the parent compound or as related metabolites. 
Repeated administration of 14C-1 abe 11 ed lasalocid sodium results 
after three days in steady tissue levels, the main target organ being 
the liver. Of the labelled liver residues some 82% were extractable 
and consisted of 15% unchanged lasalocid, 7% identified metabolites 
(5 in number) and 60% unidentified fragments. The unidentified 
portion consisted of many products each representing less than 1% of 
the extractable hepatic radioactivity. Some 15% hepatic radioactivity 
was non-extractabie. Both the extractable and non-extractable 
fractions were non-mutagenic when tested in the Salmonella reverse 
mutation test. The biotransformation products identified had no 
ionophoric properties. No information has been provided on the 
identity of the various metabolites. 
Cattle treated under field conditions with 14C-labelled lasalocid 
sodium for 2 weeks at a rate of 1.0 mg/kg body weight (approximately 
40 mg/kg feedingstuff) had total labelled residues of 6.92 mg/kg 
tissue in the liver, 0.06 mg/kg tissue in the kidneys, 0.022 mg/kg 
tissue in the fat and 0.009 mg/kg tissue in muscle when slaughtered 
within 16 hours after the last dosing. After 9 days withdrawal period 
the total labelled residues were 0.713 mg/kg tissue in the liver, 
0.019 mg/kg tissue in the kidneys and below the limit of detection in 
fat and muscle (limit of detection 0.0035 mg/kg tissue). The 
bioavailability of the liver residues was on average 24.4% as 
determined in the bile of rats fed with liver from steers treated 
with labelled lasalocid sodium. 
Cattle treated for 4 weeks under field conditions with unlabel led 
lasalocid sodium at a rate of 0.6 mg/kg body weight/day 
(approximately 33 mg/kg feedingstuff) had liver residues of lasalocid 
sodium ranging from 0.025-0.539 mg/kg tissue at zero withdrawal 
period, less than 0.1 mg/kg tissue after a 2-day withdrawal period, 
0.035 mg/kg after a 3-day withdrawal period and no detectable 
residues after a 4-day withdrawal period (limit of detection of HPLC 
method 
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0.025 mg/kg tissue). These figures do not include the 82% identified 
and unidentified metabolites of lasalocid sodium present in the liver 
but not determined by the HPLC method. For comparison with the total 
labelled residues determined by analysis of radioactivity these 
figures should be multiplied by a factor of at least 7. 
Extrapolation from the data of the study using radiolabelled 
lasalocid sodium would yield a total liver residue of approximately 
1.2 mg/kg tissue calculated as lasalocid sodium after a 5-day 
withdrawal period and about 0.71 mg/kg tissue after a 7-day 
withdrawal period. Extrapolation from the studies under field 
conditions yields total liver residues, also calculated as lasalocid 
sodium, of less than 0.18 mg/kg tissue after a 4-day withdrawal 
period and residues ranging from 0.18-3.7 mg/kg tissue at zero 
withdrawal period. 
The Committee has already delivered its opinion on the possible 
effects of lasalocid sodium on the development of bacterial 
resistance when the use as additive to feedingstuffs for chickens was 
being evaluated. Like other polyether antibiotics it is generally 
effective against Gram-positive bacteria and ineffective against 
Gram-negative bacteria and also fungi, in vivo the substance inhibits 
specifically most of the lactic acid producing bacteria in the rumen. 
It has no effect on the development of Salmonella infections and does 
not prolong the shedding period of Salmone Mae. 
The ineffectiveness against Gram-negative bacteria, particularly 
E.coli, suggests that selection of enterobacteria carrying R Plasmids 
is unlikely to occur. Enterococci and other Gram-positive bacteria 
show some degree of variation in resistance to lasalocid sodium but 
no persistent changes were noted. These effects were not accompanied 
by lowered sensitivity of the bacterial strains tested to 
antibacterial substances in common therapeutic use. 
Lasalocid sodium, when added to feedingstuffs for cattle, is 
eliminated mainly in the faeces and in small amounts in the urine. 
Studies with 14C-labelled material show that 50% of the excreted 
faecal matter is unchanged lasalocid sodium and the remainder at 
least 5 metabolites. The degradabiIity of the product in cattle 
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manure (approximate concentrations 10-12 mg/kg untreated manure, 40-
48 mg/kg dry matter) has been studied in aqueous systems in relation 
to pH, light and temperature. Though very stable in dry faeces 
concentrations fall by 30% after one month in wet faeces kept at 
37'C. Degradation varies with temperature after 1 week in slurry pits 
but always exceeds 50%. 
Spreading of dung and liquid manure from treated cattle leads to soil 
concentrations of about 0.05 mg/kg soil of which about half leaches 
out. Static and dynamic trials with different types of soil showed 
considerable removal by leaching, as well as chemical and 
microbiological degradation over 2-3 weeks. 
Lasalocid does not impair soil methanogenesis. The absence of effects 
on plant development, particularly soya, makes any deleterious 
effects on nitrifying soil bacteria unlikely. 
As stated in the previous report of the Scientific Committee there 
was no evidence of any phytotoxic effects when tested on growing 
maize, barley, tomatoes and cucumbers nor does lasalocid sodium 
affect the germination of cereals and other plant seeds. 
Lasalocid sodium is barely toxic to aquatic organisms such as 
Daphnia, goldfish, moonfish and fresh water algae. The LD 5 0 ranges 
from 2.4 mg/I to 8.0 mg/I for periods of 48-49 hours. 
5. CONCLUSIONS 
Lasalocid sodium has been shown to be effective for promoting growth 
and improving feed conversion ratios in cattle during the finishing 
period at concentrations between 10 mg and 35 mg/kg of complete 
feedingstuff. There is, however, a need to fix a maximum dose 
according to the body weight of the animal as set out in the table in 
this report. 
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Residues of lasalocid sodium are found essentially in the liver but 
are low (about 0.25 mg/kg tissue) even at zero withdrawal periods. As 
the bioavailability is only about 25% these levels are well within 
the ADI and would not require a withdrawal period. However, as the 
identity of the residues is not well defined and as these residues, 
at the levels detected, have no biological activity, the Committee 
required additional mutagenicity tests with pure lasalocid sodium. 
These additional tests establish adequately the absence of a 
genotoxic potential for the pure substance. Neither the extractable 
nor the non-extractable liver residues are mutagenic in a prokaryotic 
assay. Lasalocid sodium does not cause the development of significant 
bacterial cross-resistance to antibiotics in common therapeutic use. 
The excreted products are not prejudicial to the environment and do 
not interfere with methanogenesis or with nitrification. 
In the light of the above findings the Committee is of the opinion 
that the use of lasalocid sodium is acceptable in complementary 
feedingstuffs for finishing cattle at concentrations of 10-35 mg/kg 
but the maximum dose in the daily ration should not exceed the values 
given in the table in this report. 
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Report of the Scientific Committee for Animal Nutrition on the use of 
Efrotomycin in feedingstuffs for pigs. (Opinion expressed: 27 July 1990) 
Terms of reference (April 1986) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Has the use of the fermentation product efrotomycin at the dosages 
proposed for feedingstuffs for pigs under the different climatic 
conditions existing in the European Community significant effects on 
growth? Which component of this mixture is the active ingredient? 
Are pigs of both sexes and all age groups equally affected 
pos i t i ve I y? 
2. Is this safe for the pig? 
3. Can it result in the development of resistance in bacteria to prophy-
lactic or therapeutic preparations, or exert an effect on the 
persistence of Gram-negative bacteria in the digestive tract of the 
pig? 
4. What is the metabolic fate of efrotomycin in the pig? Does the pro-
posed use result in residues in animal tissues? If so, what is the 
qualitative and quantitative composition of these residues? 
5. Do the toxicological studies allow the conclusion that the proposed 
use does not present risks 
for the consumer? 
for the user? 
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6. What are the nature and the persistence of excreted products derived 
from efrotomycin? Can these products be prejudicial to the environ­
ment? 
7. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
Background 
Efrotomycin was the subject of an application for admission in Annex II 
Section A (Antibiotics), of Council Directive 70/524/EEC of 23 November 
1970 concerning additives in feedingstuffs^) under the following 
condi t ions of use: 
Species of animal : pig. 
Minimum and maximum doses: 2-16 mg/kg of complete feedingstuff. 
Opinion of the committee 
Efrotomycin is an antibiotic belonging to the elfamycin family. It is 
structurally a N-methyIhydroxypyridone glucoside produced by fermentation 
with Hocardia Iactamdurans. The granular premix formulation 
(Produci I*)t containing 32 g efrotomycin activity/kg, has been proposed 
for use as a growth promoter in swine rations at a final concentration of 
2-16 mg active ingredient/kg. Efrotomycin consists of 3 components: about 
65-75% A-], 1-7% B, and 2.5-10% A2. The components Α-j and A z are E 
and Ζ geometric isomers. Although the stability of the premix at 45'C has 
not been examined specifically, it is stable at 37'C for about 9 months. 
The feedingstuff containing 16 mg/kg is reasonably stable for over 3 
months at constant humidity. 10% of the activity may be lost in 6 months 
to 1 year. 
The microbiological method of analysis does not give reliable results for 
the components Az and Β below levels of 16 mg/kg. It, and the HPLC 
method of analysis, are however reliable for component ΑΊ down to the 
level of 4 mg/kg. 
(1) O.J. N· L 270 of 14.12.1970. p. 1. 
(Producil*) Registered trade name of Merck, Sharp and Dohne. 
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1. Efficacy was studied in 37 trials with pigs (23 in UK, France, 
Germany, Italy, Denmark and 14 in USA, Canada, Brazil) involving a 
total of 3600 animals including 954 controls, and doses from 2-
16 mg/kg of complete feedingstuff. The 23 European trials involved 
2612 animals and 540 controls. All these trials were conducted with 
concentrations of copper between 35-180 mg/kg feedingstuff. In 8 
trials 5 different additives (tylosin, olaquindox, virginiamycin, 
carbadox, avoparein) were used as positive controls. Daily weight 
gain and feed conversion efficiency were the zootechnical parameters. 
In the data obtained before 1986 the positive controls often showed 
no growth promoting effect due to inadequate experimental design. 
This was not noted in the European trials after 1986. The energy and 
amino acid composition of the feeds are not stated in many of the 
trials and the stated doses of efrotomycin frequently do not 
correspond with those determined by feed analysis. In several trials 
the number of animals used was small. 
For all European trials the improvement in daily growth was very 
variable at all tested doses. The same variability was observed for 
feed efficiency. The dose-response curves in these trials are not 
I i near. 
In 22 trials using doses higher than 4 mg efrotomycin/kg of complete 
feedingstuff neither growth nor feed conversion index were 
significantly. Furthermore, in some trials there was no difference in 
weight gain between 2 mg and 4 mg efrotomycin/kg of complete 
feedingstuff. In general, results appeared to be better during the 
early growing period (up to 60 days). The concomitant use of Cu 
supplementation and of castration in the European trials makes it 
difficult to assess the specific growth promoting effect of 
efrotomycin. In some trials males show a better growth response. 
2. Studies in the target species using efrotomycin at 5x (80 mg/kg 
feed), 20x (320 mg/kg feed) and 25x (400 mg/kg feed) the recommended 
inclusion level revealed no toxicologically relevant effects. 
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Transient diarrhoea and perianal erythema were seen at 400 mg/kg 
feed. No adverse treatment-related effects on body weight gain or 
feed consumption were noted at 320 mg/kg feed or less after 28 days. 
Treatment with efrotomycin did not influence reproduction parameters 
or offspring. 
Treatment of non-target species with doses up to 40 mg/kg feed 
resulted in lower feed consumption and diarrhoea in the first few 
days, disappearing within one week in sheep and cattle. In horses 
decreased feed consumption and lower body weight gains were observed 
with 16 mg/kg feed. Birds (chicken, turkey, duck, guinea fowl, quail) 
treated with efrotomycin at 4 mg/kg feed showed generally higher 
weight gain and feed conversion efficiency. Higher doses were not 
studied. No data on rabbits were available. 
Efrotomycin is a narrow-spectrum antibiotic, its activity being 
mainly due to the component A-|. Although the component A z has the 
same spectrum of antibiotic activity, its presence is too low to make 
any significant contribution. Component Β has no antibiotic activity. 
Relatively high inhibitory levels of efrotomycin are required in 
vitro. It may be more effective in vivo. Little activity was shown 
against a large number of bacterial isolates from farms except 
against Streptococcus suis, Pasteure 11 a ■u/toc/da, C/ostr i di um 
perfr i ngens, and Treponema hyodysenteriae 
There was little evidence of the development of resistance to 
efrotomycin in enterococci, col i f ores, CI. perfr i ngens and 
bacteroides species. No mutants resistant to efrotomycin developed in 
c Iostri d i a. 
The metabolic studies used the reverse isotope dilution analysis of 
the substance labelled with 1 4C at C 7 (limit of detection 0.005-
0.01 mg/kg). Tissue residues were assessed by HPLC/UV (limit of 
detection 0.005 mg/kg) which correlates well with the microbiological 
assay method. 
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Balance studies were carried out in young pigs using 14C-1 abe I I ed 
efrotomycin A-] at 16 mg/kg feed. Recovery studies were carried out 
over 48 hours only which is an undesirably brief period. 60-77% of 
radioactivity was recovered in the faeces and urine (less than 2%) 
after 48 hours with an approximate half-life of 1 day. Efrotomycin 
AT is therefore absorbed to a small extent from the gut, the target 
organ being the liver. 
Liver residue amounted to 0.16 mg/kg tissue, kidney residue to 
0.04 mg/kg and muscle 0.011 mg/kg. No radioactivity appeared in the 
fat. Live residue had fallen to 0.018 mg/kg and kidney residues to 
0.013 mg/kg within 48 hours, the half-life being 0.5-1 day. Muscle 
tissue was free from residue after 24 hours. 65-70% of the liver 
residue was efrotomycin A-|, 12-16% was non-extractable. No 
efrotomycin Β was detected in the liver. Solvent extraction caused 
analytical interference because of partial decomposition of 
efrotomycin A-). 
About 66% of the kidney residue was efrotomycin A-|. Urine contained 
no efrotomycin B, about 30% of the activity being due to efrotomycin 
A-]. The remainder were polar metabolites. 60% of the faecal 
radioactivity was efrotomycin A-| and 20% efrotomycin B, the 
remainder being breakdown products. The polar urinary and faecal 
breakdown products were not identified further. Efrotomycin Β was 
therefore not absorbed from the gut. 
The rat metabolizes efrotomycin Α-j approximately similarly to the 
pig but appears to form fewer polar metabolites. Rat liver contains 
both efrotomycin ΑΊ and a smaller percentage of polar metabolites 
than pig I iver. 
Pig stomach contents partially convert efrotomycin A-) into 
efrotomycin Β in vitro and this conversion may also occur in vivo. 
Bioavailability was not studied but in view of the low level residues 
and very short half-life this is not relevant to safety. Similarly, 
the low level of the residues for polar breakdown makes further 
identification unnecessary. 
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5. The toxicological studies involved acute oral and i.p. toxicity in 
rats and mice. Efrotomycin-Mg-aIginate was non-irritant to rabbit 
skin and eyes. Subchronic toxicity was studied in dogs and rats. Two-
year chronic studies in mice and rats produced no evidence of 
carcinogenic potential. A two-generation reproduction study in rats 
showed no treatment-related effects on reproductive parameters. 
Teratogenicity studies in mice and rats produced some evidence of 
foetotoxicity at high doses tested (2000 mg/kg b.w.) which however 
caused no maternal toxicity. Mutagenicity was studied in several test 
systems, both in vivo and in vitro. The positive result for 
efrotomycin in one in vitro test could not be confirmed in subsequent 
tests with the same and a new sample of efrotomycin. An additional in 
vitro test for induction of SCEs in cultured CHO cells was negative. 
An ADI of 0.1 mg/kg b.w. can be established based on the lowest NOEL 
of 10 mg/kg b.w. found in the subchronic dog study. However the dog 
is not as sensitive as some livestock animals. Adverse effects were 
found in pigs at 16 mg/kg b.w. 
6. Decay of the active principle in the excreta is slow in aqueous 
solution in the dark but rapid in sinlight and varies with pH. It is 
particularly rapid at acid pH but, even at pH 9, some 94% have 
decayed in sunlight after 10 hours. Days is also slow in sandy and 
clay soil. Efrotomycin shows little mobility in the soil and there is 
a theoretical possibility of accumulation unless it is destroyed by 
photodegradation. Data on biodegradation in sediment/water systems or 
activated sludge are not available. The partition coefficient 
indicates that bioconcentration in aquatic and terrestrial organisms 
is unlikely. The physical properties make dispersion in the 
environment by evaporation unlikely. Germination trials showed slight 
phytotoxicity only against maize and no significant inhibition of 
root and shoot growth in mono- and dicotyledons. Efrotomycin was not 
toxic to earthworms at concentrations up to 1000 mg/kg soil. A 
concentration of 31 mg/I had no effect on Daphnia magna and 0.13 mg/I 
did not affect algal growth. The LD50 for Salao gairdneri was 
greater than 100 mg/I. No negative effects were noted regarding 
nitrification up to 20 mg/kg in the soil. Soil methanogenesis showed 
a slight reduction and concentrations above 100 mg/l reduced methane 
production in waste water treatment plants. No tests with faeces 
containing efrotomycin 
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and its degradation products were performed. A Stauber Heubach test 
on the granulate, the premix and a complete pig feed containing 16 mg 
efrotomycin/kg showed that the premix produced only 1% of the dust 
generated from the granulate. No efrotomycin was detected in the dust 
from the pig feed. 
The zootechnical data relating to the European trials give only weak 
support to the efficacy claims for efrotomycin when used in 
conjunction with copper supplementation and castration of males. No 
data are available to Judge whether the different climatic conditions 
within the European Community affect the growth promoting action of 
efrotomycin. The US trials are adequate for substantiating the 
efficacy of efrotomycin in the absence of copper supplementation. 
Both the A^ and the B components appear to be more effective in 
younger animals and best in uncastrated males. Consideration of the 
various efficacy trials showed that the effective dose was about 
4 mg/kg of complete feedingstuff. Studies in the target species have 
shown that doses up to 16 mg/kg feed are safe for pigs. 
There was no evidence for the development of resistance to 
prophylactic or therapeutic preparations or of the persistence of 
Gram-negative bacteria in the digestive tract of the pig nor of any 
effect on Salmonella shedding. Efrotomycin A-| is absorbed to a 
small extent, undergoes biotransformation and is found In the liver 
at very low levels. The half-life of these residues is about 24 
hours. Bioavailability is not relevant for the safety of these 
residues in view of their low level and short half-life. 
The toxicological profile of efrotomycin has been fully studied, the 
ADI of 0.1 mg/kg b.w. being based on the dog study. There is an ade-
quate safety margin between the residues in the liver and the ADI. On 
this basis the use at the level of 4 mg/kg of complete feedingstuff 
does not present any risks to the consumer. The Stauber-Heubach test 
confirmed the absence of significant risk from dust inhalation from 
the premix or complete feedingstuff. 
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Efrotomycin is photodegradable, shows little mobility in soil and has 
therefore a theoretical potential for accumulation unless it is de-
stroyed by photodegradation. It does not bioconcentrate nor does it 
evaporate into the environment. It is not phytotoxic nor toxic to 
earthworms, Daphnla, fish and vegetable forms of aquatic life. It 
does not affect significantly nitrification or methanogenesis. No 
data on the effect on meat quality are available. 
In the light of the above the Committee is of the opinion that the 
use of efrotomycin is acceptable at a level of 4 mg active 
ingredient/kg of complete feedingstuff. The amount of efrotomycin 
added to the premix or the complete feedingstuff should be stated in 
terms of efrotomycin A-|, the only component analysed in feed and 
residues. 
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Report of the Scientific Committee for Animal Nutrition on the use of 
lasalocid sodium in feedingstuffs for turkeys. (Opinion expressed: 10 
July 1991). 
Terms of reference (March 1984): 
The Scientific Committee for Animal Nutrition (SCAN) is requested to give 
an opinion on the following questions: 
1. Does the use of lasalocid sodium under the conditions proposed for 
feedingstuffs for turkeys (see Background) result in residues in 
animal products or excreted products which are qualitatively or 
quantitatively different from those resulting from its use in 
chickens? 
2. If so, could these residues or excretion products be prejudicial to 
the consumer or the environment? 
3. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
Background 
In accordance with the provisions of Council Directive 70/524/EEC of 23 
November 1970 concerning additives in feedingstuffsC), as last amended 
by the Commission Directive 84/587/EEC^2^, the use of lasalocid sodium 
is authorized at Community level under the conditions set out as follows 
in Annex I, Section D, of the Directive 
(1) O.J. n· L 270. 14.12.1970, p. 1 
(2) O.J. No. L 319. 8.12.1984, p. 13 
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Spec ies of anima I : chickens for fattening. 
Minimum and maximum content in complete feedingstuffs: 75-125 ppm 
(mg/kg). 
Other provisions: withdrawal period of at least five days before 
slaughter. 
The Scientific Committee for Animal Nutrition has expressed a favourable 
opinion on this use in its report of 14 December 1982 
At present it is proposed to extend the authorization of use of this 
additive under the following conditions: 
Species or category of animals.· Complete feedingstuffs for 
turkeys 
Max i mum age.: up to 16 weeks. 
Minimum and maximum content in complete feedingstuffs: 90-125 ppm 
(mg/kg). 
Other provisions: withdrawal period of at least three days before 
slaughter. 
Opinion of the committee (July 1991) 
Much of the basic information about lasalocid sodium hás already been 
reviewed and evaluated in the Fourth Series of Reports of SCAN (see 
references). The proposal to extend the use to feedingstuffs for turkeys 
therefore requires only an evaluation of information specifically related 
to turkeys. 
1. After administration for 8 weeks of 125 or 200 mg of lasalocid sodium 
per kg in feedingstuffs to groups of 5 or 6 turkeys as from one day, 
old residues of unchanged lasalocid were determined by HPLC/TLC 
(limit of detection 25 ppb) in muscle, liver, kidney, fat and skin 
after a 1, 2 and 3 day withdrawal period. Residues at 125 mg/kg 
dosage ranged from less than 0.025 to 0.085 mg/kg fresh tissue and at 
200 mg/kg dosage from 0.025 to 2.25 mg/kg fresh tissue. No residues 
of unchanged lasalocid were detectable in any tissue after a 48 hour 
withdrawal period at 125 mg/kg, while for 200 mg/kg only skin 
contains detectable levels (0.038 mg/kg fresh tissue) after a 3 day 
withdrawal period. 
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The liver was identified as the target organ in terms of total 
residues when radiolabelled lasalocid was administered. After 5 days 
withdrawal total labelled residues were 0.85-0.89 mg/kg tissue 
lasalocid equivalents in the liver, 0.12 mg/kg in the abdominal fat 
and 0.07-0.11 mg/kg tissue in the kidney, skin and fat from non-
abdominal sites. 
These figures are very close to those reported for chickens. Un-
changed lasalocid represents only 3.8% of the total residues in the 
liver, while extractable and non-extractable residues account for 
about 40% and 50% respectively. 
Turkey excreta contained about 10% of lasalocid in unchanged form, 
the remainder representing a large number of different metabolites. 
This figure compares well with the 12% unchanged lasalocid present in 
chicken excreta. Chromatography confirmed a similar pattern of faecal 
metabolites for turkeys and chicken. 
The metabolic fate of lasalocid in the turkey has been studied using 
14C-lasalocid labelled in three stable positions of the carbon 
skeleton. A metabolic balance determination established after the 
administration of daily doses (127 mg/kg feed) for 14 days that after 
5 days of withdrawal from some 83.4% and 80.2% of the total 
administered dose had been were excreted in the droppings of the 
males and females respectively. Biliary excretion was considerable, 
indicating a significant absorption of the lasalocid. 
The metabolic fate of lasalocid was compared in chickens and rats. 
Methodological difficulties arose because the molecule is metabolized 
into a very large number of metabolites, none of which accounts for 
more than 1% of the total radioactivity in the tissues or excreta. It 
may reasonably be concluded that lasalocid is metabolized similarly 
in the turkey and chicken but differently in the rat. 
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In view of the analytical difficulties in identifying the precise na-
ture of the hepatic residues the Committee took into account 
exceptionally the very low bioavailability of these residues in 
addition to the above findings. 
The Committee concluded in the light of the metabolic data that the 
residues of lasalocid in the liver of turkeys would not present a 
danger to the health of the consumer. As reported previously (see 
references) lasalocid has been found to be non phytotoxic and not to 
have herbicida I, insecticida I or insect growth regulatory activity. 
Concentrations of drug related material in the excreta are at least 
of an order of magnitude lower than the acutely toxic levels for 
aquatic species. There are no data on the end points of the breakdown 
of the molecule in the environment nor on the environmental effects 
of the metabolites of lasalocid present in turkey excreta. However 
the instability of lasalocid in aqueous systems at all pH values, 
particularly in the presence of light or heat, and in soil, 
particularly in the presence of chicken manure, permits the Committee 
to conclude that lasalocid related material in turkey excreta is un-
likely to be prejudicial to the environment. 
The Committee is of the opinion that the proposed conditions of use 
are acceptable i.e. a minimum and maximum content of lasalocid sodium 
of 90-125 mg/kg of complete feedingstuff for turkeys up to the age of 
16 weeks but with a withdrawal period of at least 5 days before 
slaughter. This withdrawal period, which is similar to that 
recommended for chickens treated with lasalocid sodium, has been 
chosen because of the close comparability of the level and 
composition of the residues in the liver of the two species. Although 
the consumption of turkey liver from birds subject even to a zero 
withdrawal period would not lead to intakes exceeding the ADI of 
0.005 mg/kg b.w., established on the basis of long-term studies in 
rats, the Committee nevertheless considered a withdrawal period of 
5 days necessary because of the differences in metabolic handling of 
lasalocid by the rat and poultry. 
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Report of the Scientific Committee for Animal Nutrition on the use of 
Salinomycin Sodium in feedingstuffs for pigs. (Opinion expressed: 10 July 
1991). 
Terms of reference (October 1986) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Has the use of the antibiotic salinomycin (sodium salt of polyether 
of monocarboxyIic acid) at the dosages proposed for feedingstuffs for 
pigs (see Background) significant effects on the growth of the 
animal? 
2. Is this use safe for the pig? 
3. Can it result in the development of resistance in bacteria to prophy-
lactic or therapeutic preparations or exert an effect on the persist-
ence of Gram-negative bacteria in the digestive tract of the pig? 
4. What is the metabolic fate of salinomycin in the pig? Does the pro-
posed use result in residues in animal tissues? If so, what are the 
qualitative and quantitative composition and persistence of these 
residues? 
5. Do the toxicological studies of the product allow to conclude that 
the proposed use does not present risks 
for the consumer? 
for the user? 
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Are the products derived from salinomycin and excreted by the pig of 
the same nature as those excreted by the chicken? If so, can these 
products be prejudicial to the environment? 
In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
Background 
In accordance with the provisions of Council Directive 70/524/EEC of 
23 November 1970, concerning additives in feedingstuffsCi, as last 
amended by the Commission Directive 84/587/EEC of 29 November 1984Í2), 
the use of salinomycin is authorized at Community level under the 
following conditions set out in Annex I, Section D, of the Directive: 
- Species of anima I : chickens for fattening. 
- Dosage: 50-70 mg/kg of complete feedingstuff. 
- Other provisions: use prohibited at least five days before 
slaughter. 
The use of salinomycin sodium in other animal species, which was also re-
quested, is not authorized in the Community. In this connection, the 
Scientific Committee for Animal Nutrition expressed a provisional opinion 
in 1982 and, with regard to the chicken, a final opinion in 1984. 
Additional files intended for supporting the application for the use of 
the product as growth promoter in pigs under the conditions mentioned 
below are presently available: 
Use levels: 
- piglets up to 4 months: 30-60 mg/kg of complete feedingstuff. 
- pigs up to 6 months: 15-30 mg/kg of complete feedingstuff. 
(1) O.J. No L 270. 14 Dec 1970 p.1. 
(2) 0.J. No L 319, 8 Dec 1984 p.13. 
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Opinion of the committee 
Salinomycin is a polyether antibiotic of known structure. It is a 
monobasic carboxy lie acid containing five cyclic ether rings. 
1. Salinomycin has been used in a large number of trials both in the 
rearing of piglets and in fattening pigs in some 14 countries, 
including some in the EEC. The results are very variable and not easy 
to interpret because the pig populations involved were not 
homogeneous and the rearing conditions frequently not standardised. A 
consistent dose-effect relationship cannot be derived. However, a 
definite positive though rather flat response was discernible with 
increasing amounts of salinomycin in the feeds. This supports the 
existing practical experience of having to use more than the apparent 
lowest effective dose in view of the large inter-individual 
variations in biological response and the known differences in animal 
husbandry practice. A reasonable estimate of the doses giving a 
significant effect on growth would be 50 mg/kg feed (range 30-60) for 
piglets up to 4 months and 20 mg/kg feed (range 15-30) for pigs up to 
6 months. 
2. A six months study in pigs showed some hepatotoxicity at high doses, 
the NOEL being 2.5 mg/kg b.w. This is well above the dose proposed 
for growth promotion. Toxic signs following overdose in pigs, 
apparent after 5 days, are respiratory problems, anorexia, ataxia, 
inability to stand, hematuria and a mortality of about 10%. 
Histopathology indicates acute degenerative myopathy. 
In conjunction with administered tiamulin there is a dose-dependent 
increase in toxicity of salinomycin due to a reduction in excretion. 
The compatibility of tiamulin and salinomycin is influenced mainly by 
the total combined administered dose/unit time, estimated to be about 
6 mg/kg b.w. There should also be an interval of at least 7 days 
between administration of tiamulin and salinomycin or vice versa, 
unless doses are of the order of 60 ppm salinomycin and 30-40 ppm 
tiamulin per pig. Attention is drawn to the possibility of adding a 
warning remark to the label of ionophores (salinomycin, monensin, 
narasin, maduramicin, lasalocid) stating that animals, including 
birds, should not be treated with products containing tiamulin while 
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receiving, and for at least 7 days before or after receiving, feed 
containing salinomycin because severe growth depression or death may 
result. 
Salinomycin is moderately effective only against Gram-positive bacte-
ria. No evidence for selection pressure or selection of indigenous 
enterococci with multiple-resistance Plasmids was found. No cross re-
sistance to 6 antibiotics used in human medicine was found and there 
is a lack of structural resemblance to chemotherapeutic agents used 
in human medicine. No resistance was observed in coccidia nor stable 
resistance by chromosomal mutations in Staph, aureus in vitro. 
Salinomycin alters to a small extent the relative levels of Gram-
positive and Gram-negative bacteria in the intestine of pigs. There 
appears to be no need for concern over the possible development of 
bacterial resistance in the Gram-negative bacteria in the digestive 
tract of the pig. 
Metabolism studies in mice, rats and chicken using oral doses of 
14C-labelled salinomycin showed that over 90% is excreted in the 
faeces within 48-72 hours, less than 5% in the urine and negligible 
amounts in the expired air. Small amounts of 14C-saI¡nomycin are 
found in the liver and bile after 48-72 hours. The amounts of 
radioactivity in rat and mouse tissues, particularly in the liver, 
were considerably larger than in chicken tissues. 
Salinomycin is rapidly metabolized in the gut and liver to numerous 
metabolites, mainly mono-, di- and tri hydroxylated derivatives. The 
spectra of metabolites in rat and mouse liver were qual i tat i ve I y and 
quantitatively similar, the spectrum in chicken liver being 
qualitatively similar but quantitatively different. Only 2-8% of 
liver radioactivity was non-extractable in the three species. 
Metabolism is slowest in the chicken. A similar study with l e -
sali nomycin in dogs indicated similar metabolites to those found in 
the chicken at about the same order of magnitude. 
Salinomycin is rapidly and extensively absorbed and metabolized by 
pigs when administered by the oral route. An average 83.5% of the 
radioactivity is excreted in the faeces with little intact 
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salinomycin being present, in urine around 2.1% is excreted. After 4 
days, residues in the liver are 0.1mg/kg and less than the detection 
limit in muscle, kidney and fat (limit of detection of radiochemical 
method 0.01 mg/kg). Pig bile contains mainly the di- and 
trihydoxylated derivatives, while liver also contains other 
hydroxylated products, notably the monohydroxy derivative also found 
in rabbit i iver. 
Extensive residue studies in broilers, turkeys, rabbits and pigs 
showed no detectable residues after 24 hours withdrawal using a 
microbiological method (limit of detection 0.01 mg/kg). After single 
dose administration to pigs 71-88% were found in the gastro-
intestinal tract after 12 hours, radioactivity being only detectable 
in the liver. Repeated dose administration produced a liver residue 
level of 1.5 mg/kg after 8 hours withdrawal, failing to 0.4 mg/kg 
after 12 hours (monohydroxy-salinomycin absent, only di- and 
trihydroxy-salinomycin present), 0.2 mg/kg after 24 hours and 0.06 
mg/kg after 60 hours, when analysed by a radiochemical method with a 
limit of detection of 0.01 mg/kg. When analysed by a microbiological 
assay with a limit of detection of 0.02 mg/kg no residues could be 
detected after 24 hours in the liver. The half-life of elimination 
was 2-3 hours during the first 12 hours after withdrawal and about 17 
hours thereafter. 
Pigs receiving repeated doses of sal inomycin-containing mycelium in 
concentrations up to 200 mg/kg feed produced residues after 24 hours 
in the cutaneous fat of only 2 animals given 50 mg/kg feed. In 
another experiment no tissue residues were detected after 16 hours 
withdrawal. In the opinion of the Committee residues in the liver of 
pigs have fallen to an insignificant level after 24 hours withdrawal, 
the ionophoric activity being lower than residues in chicken liver. 
No residues are detectable in any other tissue of pigs after 12 hours 
withdrawal. 
5. Most of the toxicity studies were performed with the dried mycelium 
and a few with 87-95% pure salinomycin. Acute toxicity studies in 
mice, rats, chicken, rabbits, dogs, pigs, bulls and horses showed 
oral LD50 values ranging from 21-60 mg/kg b.w.; for mice, rats, 
chickens and rabbits the signs of toxicity were mostly neurological. 
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Pigs, bulls and horses were increasingly sensitive in that order, 
toxic effects occurring mostly in the liver and myocardium. Acute 
dermal toxicity tests in the rat showed salinomycin to be moderately 
irritant. Salinomycin was non-ant¡genie and caused no immediate or 
delayed hypersensitivity in guinea-pigs. Subchronic studies were 
carried out in mice, rats, dogs and pigs. The target organs of 
toxicity were liver and spleen in mice ( NOEL 3.75 mg/kg b.w.) and 
rats ( NOEL 2.5 mg/kg b.w.), the nervous system in dogs ( NOEL 1 
mg/kg b.w.) and the liver in pigs ( NOEL 2.5 mg/kg b.w.). 
Two-year chronic toxicity studies were carried out in mice and rats 
and also a study over 2 1/2 years in rats using mycelium. Most of the 
observed adverse changes concerned organ weights and clinical 
biochemistry values but there was no evidence of carcinogenicity. The 
NOEL was <1.4 mg/kg in the mouse study and 2.5 mg/kg b.w. in the rat 
study. 
A two-generation reproduction study in rats showed a NOEL of 5 mg/kg 
b.w. Embryotoxici ty and teratogenicity studies in mice and rabbits 
revealed maternal and foetal toxicity in mice with a NOEL 4 mg/kg 
b.w. Rabbits showed increased resorptions most probably due to mater-
nal/foetal toxicity with a NOEL of 0.25 mg/kg b.w. but no 
teratogenicity was observed. 
The bioavailability of 14C-saI inomycin in pig liver was found in 
rats to be 10-31% of the administered dose. The ionophoric activity 
in pig liver was markedly lower than in chicken liver due to lower 
amounts of salinomycin. Genotoxicity was absent when salinomycin was 
tested in a bacterial system, a host-mediated assay in mice, a 
recessive lethal assay in DrosophiI a and a gene mutation test in 
mouse lymphoma cells. From the available toxicological studies an ADI 
of 0.003 mg/kg b.w. may be determined on the basis of the NOEL in 
the rabbit embryotoxicity study. It may be concluded from a 
consideration of the toxicity studies, the ADI of 0.003 mg/kg b.w. 
and the very low residues in pig liver that the proposed use of 
salinomycin does not present a risk to the consumer. As regards the 
user it should be noted that the substance is a dermal irritant. 
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1.4-2.8% of the radioactivity of 14C-labelled salinomycin fed to 
pigs are excreted in the urine and 81-86% appear in the faeces within 
4 days, with small amounts of intact salinomycin present. Only about 
1-5% of the microbiological activity in the feed is found in the 
excreta from broilers. Similar excretion patterns were found in other 
species (fowls, rats, mice, dogs). Because most of the metabolites 
have no antibiotic activity it appears likely that pig excreta, like 
chicken excreta, carry only very low antibiotic activity. There are 
no data on the toxicity of the faecal metabolites in pig manure. 
There are no data on the stability of salinomycin in pig excreta 
during storage. Since salinomycin rapidly disappears from chicken 
manure, the concentration dropping from 0.04 ppm to 0.01 ppm within 6 
days at room temperature, one can assume similar rates of 
disappearance from pig excreta. 
The half-life of salinomycin in soil was 40-50 hours when measured 
microbiological ly (limit of detection 0.01 mg/kg), only 1% remaining 
after 21 days, thus constituting practically no risk of accumulation. 
No data are available on leaching from soil or on the breakdown prod-
ucts in soil. Only very low concentrations of salinomycin are likely 
to be found in soil when using pig manure as fertilizer. 
Salinomycin and its metabolites have a low toxicity for Daphnia 
(EC50 24 h : 43 mg/l), no effect being observed at 21.5 mg/1. Fish 
toxicity (Golden or f -Leuciscus idus) was also low (LD50 96 h : 30 
mg/l). No effect was observed at 22.4 mg/l. 
Total methane production from fresh pig manure from treated pigs was 
increased by 5% over that from untreated pigs. Salinomycin in the 
faeces of cattle reduced methane production by about 15%. At a 
salinomycin level of 8 mg/kg in soil (300 times the maximum 
concentration possible in soil under practical conditions) 
nitrification was slightly delayed. However no similar data are 
available for the effect of actual pig manure, i.e. of the 
metabolites, although most are devoid of antibiotic activity. 
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Plant growth was slightly inhibited at doses of 12.5-200 mg 
sa I inomycin/m2 for carrots, kohlrabi, chinese cabbage, potatoes and 
sugar beet. No uptake into plants was noted at 14 mg/kg soil. These 
tests were done with pure salinomycin and not with manure containing 
metabolites. These observations indicate that possible harm to the 
environment is unlikely at the concentrations reached by normal use 
of pig manure. However, data on the effect of the metabolites are 
lacking. 
In the light of the available evidence the Committee is of the 
opinion that the use of salinomycin in the feedingstuffs of pigs at 
the proposed levels could be admitted. A similar warning remark 
regarding interaction with tiamulin should be included on the label 
of ionophore treated feed and tiamulin preparations. 
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Report of the Scientific Committee for Animal Nutrition on the use of 
Narasin + Nicarbazin in feedingstuffs for chickens. (Provisional opinion 
: 10 July 1991). 
Terms of Reference (June 1990) 
The Scientific Committee for Animal Nutrition (SCAN) is requested to give 
an opinion on the following questions: 
1. Has the use as a coccidiostat of Narasin (polyether of monocarboxylic 
acid produced by Streptoayces aureofaciens) plus Nicarbazin 
(equimo I ecu lar complex of 1,3-bis (4-nitrophenyI)urea and 4,6-
dimethylpyrimidine-2-ol) under the conditions proposed for its use as 
an additive for fattening chickens (see background) significant 
effects on the prevention of coccidiosis in this animal species? 
2. Is this use safe for the chickens? 
3. Can it be monitored in animal feedingstuffs? 
4. Can it result in the development in bacteria of resistance to 
prophylactic or therapeutic preparations? 
5. What is the metabolic fate of the whole product Narasin+Nicarbazin in 
the chicken? Are the two component products compatible? Does the pro-
posed use result in residues in animal tissues? If so, what are the 
qualitative and quantitative composition and persistence of these 
residues? 
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6. Do the toxicological studies allow to conclude that the proposed use 
does not present risks 
- for the consumer? 
- for the user? 
7. What are the nature and the persistence of the excreted products de-
rived from Narasin+Nicarbazin? Can these products be prejudicial to 
the environment? 
8. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
Background 
N a r a s i n ^ ) and Nicarbazin^ 2) are coccidiostats already included in sec-
tion D (Coccidiostats and other medicinal substances) of the Annex I list 
to Council Directive 70/524/EEC of 23 November 1970 concerning additives 
in feedingstuffs^). 
The preparation Narasin+Nicarbazin was the subject of an application for 
admission in the same section D (Coccidiostats and other medicinal 
substances) of this Council Directive 70/524/EEC (3) under the following 
condi t ions of use: 
- Species of animal : chickens for fattening. 
- Use level : 40+40 to 50+50 mg/kg of complete feedingstuffs. 
- Other provisions: Use prohibited at least five days before slaughter. 
Opinion of the Committee 
1. Narasin is a pol yet her antibiotic produced by deep culture 
fermentation of a strain of Streptotyces aureofaclens. Its chemical 
structure shows it to be a monobasic carboxylic acid containing 
5 cyclic ether r ings. 
(1) J.O. No. L183. p.15 (11.07.1984) 
(2) J.O. No. L310. p.19 ( 5.11.1986) 
(3) J.O. No. L270. p. 1 (14.12.1970) 
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Nicarbazin is an equimolecular crystalline complex composed of 67.4-
73.0% 4,4'-dinitrocarbaniI ide (DNC) and 27.7-30.0% 2-hydroxy-4,6-
dimethyl-pyrimidine (HDP). 
In a large number of tests, using various combinations ranging from 
10+10 to 60+60 mg/kg of feedingstuff of each substance against 
5 lineria strains producing intestinal coccidiosis and 1 strain 
producing caecal coccidiosis as well as mixed Elmeriä infections, a 
combination of 50+50 mg/kg of complete feedingstuff has been the most 
efficient with regard to growth, improved feed efficiency, lesion 
control and oocyst elimination. A clear dose-response relationship 
has been demonstrated. Efficiency of the combination has been 
compared with feedingstuff containing 70 mg/kg Narasin or 125 mg/kg 
Nicarbazin but not with other coccidiostats. Because the 50+50 
combination does not eliminate oocysts completely, sufficient remain 
to induce immunity. The 50+50 combination is effective against 
resistant, strongly pathogenic single strain infections and mixed 
infections. However, with this dosage there are the occasional cases 
where weight gain is reduced and feed efficiency impaired. 
2. The use of the 50+50 mg/kg of complete feedingstuff combination is 
safe for chicken. The occasionally observed smaller weight gain or 
impaired feed efficiency is acceptable in the absence of any other 
adverse effects in chicken, when compared to the risk of 30 - 35% 
mortality from untreated infection. 
3. There are adequate analytical methods for assaying the pure drugs and 
the tissue residues. Narasin is assayed by TLC with bioautographic 
overlay using Streptococcus faeciua (limit of detection 0.005 mg/kg). 
Nicarbazin is assayed mostly by determining the DNC component with 
HPLC/UV (limit of detection 0.10 mg/kg), less frequently by HDP 
determination using FID GLC (limit of detection 2 mg/kg). 
4. Of the two components only Narasin has antibiotic activity. The 
evaluation by SCAN is reported in the Fourth Series of Reports. SCAN 
concluded that none of the gram-positive bacteria, the only kind 
against which Narasin is active, showed cross-resistance to a variety 
of c I i nica I 
- 44 -
antibiotics tested, even when transient resistance to Narasin 
developed. There appears therefore to be no need for concern over the 
possible development of bacterial resistance. A separate experiment 
on the possible effect of Nicarbazin on the antibacterial activity of 
Narasin against E. coll, Bacteroldes and Staphylococci was negative, 
showing no change in MIC for the susceptible and non susceptible 
strains examined, however only little material was used. The normally 
susceptible Staphylococci viere found to be unexpectedly resistant to 
the action of narasin. 
No explanation was offered for this observation. It would therefore 
be desirable to repeat the experiment or to provide an explanation 
for the change in the MIC values. Because preparations effective 
against gram-positive bacteria frequently extend Salmonella shedding 
through an imbalance in the intestinal flora, it could be desirable 
to determine the effect of the combination on Salmonella shedding, in 
a separate experiment Nicarbazin was shown to have no antibacterial 
effect on a selection of bacterial strains. 
Nicarbazin is largely absorbed by the chicken, HDP is excreted mainly 
in the urine and DNC mainly in the bile and faeces. HDP is rapidly 
metabolized and disappears from all tissues after a 5-day withdrawal 
period (limit of detection 0.3-0.4 mg/kg tissue). No identification 
of metabolites is available. DNC is metabolized slowly with residues 
persisting mainly in the liver, amounting to 0.06-0.08 mg/kg tissue 
DNC equivalents after 11 days withdrawal. HDP therefore contributes 
only 4.5% of the total Nicarbazin residues. Use of 14C-labelled DNC 
in the chicken indicates the existence of 2 main metabolites which 
are acetylated amines arising from the reduction of one or both nitro 
groups. A third minor metabolite results from cleavage of the 
carbanilide group followed by reduction and acetyl at ion of the nitro 
group. Excreta consist mainly of DNC plus small amounts of the 
3 metabolites. Liver residues consist mainly of about 80 % DNC, less 
than 12% metabolites (M1 + M3) and some 3.3% unidentified matter. Me-
tabolism in the rat is similar to that in the chicken. 
Narasin is well absorbed and largely excreted in the bile. Excreta 
contain 6 major metabolites which incorporate the dihydroxy and 
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trihydroxynarasin structure. In total they account for only 20% of 
the parent antibiotic activity and for a very weak ionophoric 
activity. The metabolism in the rat is similar. At zero withdrawal 
time there is no measurable radioactivity in muscle and a rapid 
decline in other tissues. After three days the liver and skin contain 
0.04 and 0.025 mg/kg Narasin equivalents respectively. 5% of the 
total liver radioactivity and 50% of the total radioactivity in fat 
at zero withdrawal time was Narasin. None could be detected after 
3 days withdrawal using a microbiological assay (sensitivity 
0.005 mg/kg). 
Narasin does not change the metabolic pathway of DNC although the 
metabolic rate seems to be changed. Residues are higher by 25, 50, 
38, 41 and 35% in liver, muscle, kidney, fat and skin respectively 
which implies an effect on metabolic flux rates. 90 % of DNC 
disappears after 3 days and 98% after 5 days in all tissues. Residues 
after 5 days are less than 0.025 mg/kg DNC equivalents in muscle, fat 
and skin, 0,22 mg/kg in liver and 0.14 mg/kg in kidney. After 7 days 
liver residues amount to 0.06 mg/kg, kidney residues to 0.03 mg/kg. 
Unchanged DNC is the major residue (over 80%) in fat and skin but 
less in muscle as determined by HPLC (limit of detection 0.05 mg/kg). 
60% of liver radioactivity at zero withdrawal time and 45% after 
5 days are DNC. The corresponding kidney residues are 25% and 12% 
respect ively. 
No data are available on the effect of Narasin on HDP residues. Al-
though no direct data on the effect of Nicarbazin on Narasin 
metabolism are available, there is evidence that the residue pattern 
of Narasin is not modified. 
In chickens, raised with 125 mg/kg feed of Nicarbazin, a steady state 
residue level of 240-390 /xg/kg liver and 8-10 Mg/kg muscle is still 
found after 3-4 weeks withdrawal due to cross contamination from 
stable Nicarbazin residues in the litter. Despite the low tissue 
residues and the absence of significant differences there is a trend 
to increasing residue levels with time. Moreover the use of an 
average of 4 chickens as the experimental unit per time period makes 
statistical interpretation difficult. Comments are therefore required 
on this situât ion. 
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6. Narasin and nicarbazin have been individually assessed for their 
toxicity in the chicken, the rat and the mouse. These data are 
summarized in the Fourth Series of Reports of SCAN. The ADI then 
established for Narasin was 0.0038 mg/kg b.w. and for Nicarbazin the 
ADI was 0.20-0.24 mg/kg b.w. The ADI applies to the mixture of DNC + 
HDP. Separate AD I s were not established for DNC or HDP. Studies in 
chickens with various combinations showed that the NOEL was 62.5 + 
62.5 mg/kg feed. Studies in laboratory animals involved acute 
toxicity, dermal and ocular toxicity but hypersensitivity and 
inhalation toxicity with the granular material were not tested. A 90-
day study in rats, using various combinations, showed no treatment-
related effects except for a slight reduction in body weight for the 
60+60 combination. 
Neither Narasin nor Nicarbazin have shown any carcinogenic potential 
in long-term studies. Extensive mutagenicity studies have shown no 
evidence of genotoxici ty. Since the tissue residues were not 
qualitatively different from those arising from use of the single 
compounds, long-term studies o n the combination are not considered 
necessary. 
A teratogenicity study in rats showed no teratogenic potential, the 
no-effect-1 eve I with respect to maternal and foetal toxicity being 
0.75+0.75 mg/kg b.w. 
Bioavailability was not studied because of the very low residues. 
The Committee considered that the use of the combination did not 
present any toxicological risk for the consumer or the user. 
7. The only data available on the substance and metabolite levels in 
chicken excreta concern the two constituents separately. Excreta con-
tain primarily parent DNC and small amounts of 3 metabolites. At the 
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recommended dosage of 50 mg/kg feed Nicarbazin about 40 mg/kg of drug 
related material in the excreta could be estimated, of which about 28 
mg/kg excreta is DNC equivalents and 12 mg/kg HDP equivalents. Almost 
99% of Narasin appears in the excreta, hence a 50 mg/kg feed dosage 
would result in 46 mg/kg excreta of which 30% or 14 mg/kg excreta is 
parent narasin, while 20% or 9 mg/kg excreta are hydroxylated 
metabolites. The fate of the remaining 50% is not known. The 
antibiotic activity of the excreted products is however low. There 
are no data on the biodegradation of Nicarbazin or its metabolites in 
chicken manure. Narasin does not degrade in chicken manure to any 
significant extent even after 18 months storage. 
The DNC component of Nicarbazin is very stable in soil with a half-
life of about 49 weeks. The degradation products have not been 
determined. There is no leaching from treated soil as demonstrated by 
radioactivity measurements and absence of formation of 14C02- The 
behaviour of the water soluble HDP is not documented nor is there any 
information available on the degradation products of HDP. 
Narasin degrades rapidly in soil, some 92% within 4 weeks, 
particularly in the presence of Nicarbazin. A similar kinetic profile 
is obtained with chicken litter containing Narasin. The degradation 
products of Narasin are unknown. Basic soils leach more Narasin but, 
as it is practically insoluble in water, there is unlikely to be any 
significant passage into surface waters. 
The acute NOEL for the combination is 0.5 mg/l for Daphnla magna, 
the 48 h EC50 is 20.65 mg/l. The acute NOEL is 1.80 mg/l for the 
Bluegill and 0.16 mg/l for the Rainbow trout. 
No drug-related phytotoxici ty is noted when seeds of corn, soybean, 
wheat and tomato are fertilized with chicken excreta from birds fed 
the 50+50 combination. Levels over 16 mg/kg soil reduce growth and 
cause sublethal toxicity after 7 days in Luabricus terrestris. 
Toxicity is almost entirely attributable to Narasin. Metabolites have 
not been specifically investigated. 
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Nitrification is not affected and no effects on methanogenesis are 
observed. 
The Committee concluded that in view of the relatively low concentra-
tion of parent drugs and metabolites in chicken excreta, the low 
solubility of Narasin and the DNC component of Nicarbazin in water, 
the indirect evidence of lack of bioaccumulation of Narasin, and the 
absence of data on significant environmental toxicity, no adverse 
effects on the environment would be expected under ordinary 
conditions of use. Data on the fate of HDP and the unidentified 
metabolites of Narasin are desirable. 
8. On the basis of the above data the Committee is of the opinion that 
the use of Narasin+Nicarbazin can be admitted without risks in the 
feedingstuff for chickens at the levels provisionally authorized of 
50+50 mg/kg feedingstuff and with a withdrawal period of at least 5 
days before slaughter. It would be desirable to obtain information 
on: the metabolic fate of HDP; on the effect of Narasin on HDP 
residues; on the unidentified metabolites of Narasin, on the 
biodegradation products of Narasin, Nicarbazin and their metabolites 
in chicken manure and the soil; on the fate of HDP in the soil; and 
on the effect of administration of the combination on Salmonella 
shedding. 
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Report of the Scientific Committee for Animal Nutrition on the use of 
Diclazurii In feedingstuffs for Chickens. (Opinion expressed: 10 July 
1991) 
Terms of reference (June 1990) 
The Scientific Committee for Animal Nutrition (SCAN) is requested to give 
an opinion on the following questions: 
1 Has the use as a coccidiostat of Diclazurii (2,6-dicloro-alpha-(4-
chlorophenyI)-4-(4,5 dihydro-3,5-dioxo-1,2,4-tr iazin-2(3H)-yI) 
benzeneacetonitri le) under the conditions proposed for its use as an 
additive for fattening chickens (See Background) significant effects 
on the prevention of coccidiosis in this animal species? 
2 Is its use safe for the chicken? 
3 Can it be monitored in animal feedingstuffs? 
4 Can it result in development of resistance in bacteria to 
prophylactic or therapeutic preparations? 
5 What is the metabolic fate of Diclazurii in the chicken? Does the 
proposed use result in residues in animal tissues? If so, what are 
the qualitative and quantitative compositions and persistence of 
these residues? 
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6 Do the toxicology studies allow to conclude that the proposed use 
does not present risks.· 
for the consumer? 
for the user? 
7 What are the nature and the persistence of the excreted products de­
rived from Diclazurii? Can these products be prejudicial to the envi­
ronment? 
8 In the light of the answer to the above questions, are the proposed 
conditions of use acceptable? 
Background 
Diclazurii was the subject of an application for admission in Section D 
(Coccidiostats and other medicinal substances) of Council Directive 
70/524 EEC^1) of 23 November 1970 concerning additives in feedingstuffs 
under the following conditions of use: 
Species of anima I : chicken for fattening. 
Use level : 1 ppm in the feed. 
Other provisions: use prohibited at least three days before 
slaughter. 
Opinion of the Committee 
Diclazurii is a slightly yellowish to beige powder with a melting point 
at 292­297 *C and with a maximum impurity level (by HPLC) of about 1.5%. 
Chemically Diclazurii is a 2,6­chloro­alpha­(4­chlorophenyI)­4­(4,5­
dihydro­3,5­ dioxo­1,2,3­triazin­2(3H)­yI) benzeneaceton'i tri le, a 
compound practically insoluble in water and moderately soluble in Ν­
α ¡methyl formam i de (3.26%) and DMSO (4.8%). Its use in feedingstuffs, as a 
premix prepared by adding 5 g to 995 g of partially deproteinized soya 
flour, is recommended at a final level of 1 ppm. 
1 From preliminary cage­trials performed, in EEC and extra­community 
countries, by administering the additive (from 0.5 up to 10 ppm in 
(1) J.O. No. L270 p.1 (14.12.1970) 
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feed) to chickens infected by a single Eimeria strain or mixed 
E isteria strains, Diclazurii showed anticoccidial activity at all the 
doses tested. 
Floor pen trials performed in Belgium, Germany, South Africa, 
Yugoslavia, Spain, Italy, United Kingdom, USA and Denmark on some 
thousand animals revealed a complete anticoccidial activity of the 
active principle at the dose level of 1 ppm in feedingstuffs. 
The same finding emerged from field trials on spontaneously infected 
chickens in which the proposed level of 1 ppm in feedingstuffs 
consistently improved the intestinal lesion scores and the productive 
performance of treated animals. 
The exact mode of action of Diclazurii is not known but it has a 
potent coccidicidal action on some E. strains (f. tenella and E. 
acervulIna) and coccidiostatic action on others. 
Administration of Diclazurii, at the proposed level in feedingstuffs 
(1 mg/kg), to chickens proved to be safe for these animals. When 
broiler chickens were fed for 37 days from birth with a diet 
fortified with 25 ppm of the drug (i.e. 25 times the recommended 
dose) they showed no signs of intolerance. This finding indicates a 
very large safety margin for Diclazurii in the target species, 
identical conclusions were drawn from experiments performed on female 
and male breeding broilers, fed with a diet at 5 ppm of Diclazurii 
for 28 and 42 days respectively, as well as on ducks and turkeys, 
receiving for 7 days diets fortified with Diclazurii at the level of 
10 and 100 ppm respectively. 
Comparative tolerance experiments, carried out in mammals, showed . 
that rabbits fed with a 20 ppm Diclazurii diet for 16 days did not 
show any sign of distress or malaise, horses well tolerated a daily 
oral dose of 1 mg/kg b.w. for 6 consecutive days and dogs and cattle 
an oral dose as high as 10 mg/kg b.w. 
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The active principle may be monitored in animal feedingstuffs by 
means of a GC-method (detection limit - 30 ppb) or of a HPLC-method 
(detection limit - 100 ppb). An HPLC-method has also been described 
which allows the detection of the active principle in biological 
samples from treated animals at the sensitivity level of 50 ppb 
(plasma, muscle, liver and kidney) and of 100 ppb (skin and fat). 
No evidence of possible bacterial resistance has been reported. Since 
the additive is practically devoid of antibacterial as well as 
ant¡mycotic properties, up to a concentration of 100 /¿g/ml, it is 
unlikely that the use of Diclazurii wil I resu 11 in development of 
resistance to prophylactic or therapeutic preparations. 
No resistance to Diclazurii has been observed in any of 119 E i merla 
strains collected from naturally infected pens. Though data on the 
long-term use of Diclazurii in the field are not available, some 
experiments In vitro have shown occasional coccidial resistance 
developing after 13 contact-passages in media containing 0.1 ppm of 
the additive, thus based on available data, the induction of 
resistance is a slow occurring phenomenon. 
Diclazurii is excreted at a relatively slow rate (50% after 24 hours, 
85% and 95% after 5 and 10 days respectively), mainly through the 
faeces. It is metabolized to a limited extent, the additive being 
mainly excreted unchanged. A major metabolite accounting for 5.6-8.3% 
of the administered administered was detected in the excreta as well 
as nine other compounds all accounting for less than 2% in total. As 
none of these metabolites were found in the plasma and tissues, it 
was hypothesized that they are produced by the intestinal flora. The 
main metabolite was tentatively identified as 4-amino-2,6-dichloro-
alpha-(4-chlorophenyI) benzeneacetonitri le resulting from the opening 
of the triazine ring. 
In the rat Diclazurii showed very poor absorption and a metabolic 
pattern differed from that observed in the chicken. Following 
repeated 14C-1 abe 11 ed Diclazurii administration at 1 ppm level, 
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kinetic analyses showed the same monoexponentiaI decline 
(t-j/2 - 50-60 hours) of the total radioactivity in the plasma and 
tissues during the withdrawal period. Liver proved to be the target 
tissue. The total residues, expressed as unchanged Diclazurii, were 
386 ng/g after 6 hours and 240, 187 and 107 ng/g (ppb) after 24, 72 
and 120 hours respectively. 
Of these residues unchanged Diclazurii represented 95.8, 84.2, 74.5 
and 79.9% respectively, the metabolites identified in the excreta did 
not account for the remaining radioactivity. After a 3 day withdrawal 
period residues were below the practical detection limit of 
Diclazurii in the muscle, the skin and the fat. These results were 
confirmed from a study carried out under field conditions using 
unlabel led Diclazurii at the proposed dosage. 
The MRLs calculated according to different withdrawal times from 0 to 
10 days lie consistently under the calculated ADI, i.e. 0.022 mg/kg 
b.w. which corresponds to 1.32 mg for a 60 kg human consumer. 
6 The data on acute (oral LD50 higher than 500 mg/kg b.w. in mice, 
rats, dogs and chickens) as well as chronic toxicity (NOEL at 2.2 and 
3.15 mg/kg b.w./day oral administered for 24 months in mice and 30 
months in rats respectively) indicate low general toxicity. The NOEL 
in the mouse study has been used for establishing the ADI of 
0.022mg/kg b.w.. Diclazurii is devoid of eye irritating properties 
(rabbit) or sensitizing potential (guinea-pig), nor is it mutagenic, 
teratogenic or carcinogenic in animal tests. Taking into account 
these data and those emerging from the metabolic studies, the 
Committee is of the opinion that the proposed use of Diclazurii 
should not result in risks either for the consumer or the user. 
7 Because of the high stability of Diclazurii, a major concern for the 
Committee has been that Diclazuril's slow degradation rate might 
result in some accumulation in the environment. Thus Diclazurii in 
different soil types degrades with a half-life longer than 74 days 
and that its degradation is only slightly enhanced when in manure. 
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Studies on the potential of Diclazurii for environmental effects have 
indicated however that they may be predicted to be insignificant 
because of its low toxicity and low inclusion level in feed. 
Based on the concentration found in the excreta (280 to 710 Mg/kg) 
and a manuring regimen of 10 tons/ha/year on the same pasture without 
any degradation or migration of the residues, this could yield an 
accumulated burden of Diclazurii up to 2.8 - 7.1 /¿g/kg (ppb) soil per 
annum, i.e. a pollution level greatly below not only the toxic, but 
also the effective concentration of the compound in the complete 
feed. In view of this observation, although some accumulation in the 
environment of this persistent compound may occur, it is anticipated 
not to result in ecotoxicological hazards. 
The conditions of use of Diclazurii proposed by the Commission, i.e. 
a provision of a 3-day withdrawal period can be accepted by the 
Committee since this withdrawal period includes a high margin of 
safety. 
References 
Dossier submitted by Janssen Pharmaceutica 
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Report of the Scientific Committee for Animal Nutrition on the use of 
Propane-1,2-diol (Propylene glycol; 1,2-Propanediol), as a feed additive 
in the feedstuffs for cats. Provisional opinion expressed: 15 January 
1991 . 
Terms of reference (November 1990) 
1. May Propane-1,2-diol (E-490), at the level permitted in the feeding-
stuffs (see background), adversely affect the health of the cats? 
2 Is the level permitted in feeding-stuffs such that an usage distinct 
from that of heading G ("preservatives") of Council Directive 
70/524/EEC is excluded? 
3. Can the maximum level be reduced from its permitted level (see 
background) without affecting the desired "preservative" properties 
in feedingstuffs for cats? 
4. Can other additives listed under the same heading G ("preservatives") 
satisfactorily replace Propane-1,2-diol? 
Background 
Additive E-490 is included in Annex I of Directive 85/520/EEC of 11 
November 1985 amending the Annexes to Council Directive 70/524/EEC 
concerning additives in feeding-stuffs^1) under heading G 
(1) O.J. No. L319. 08.12.84.P.13. 
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(Preservatives) at a maximum level of 75 000 mg/kg (equivalent to 7.5 % 
w/w fresh matter basis). It is claimed that when the additive is fed to 
cats over a prolonged period of time, erythrocytes may develop oxidative 
damage to the haemoglobin, Heinz body formation and, possibly, reduced 
resistance to oxidative stress. Therefore the Commission Services would 
like to know if the permitted amount will lead in practice to 
significant higher levels when expressed per unit dry matter basis, and 
whether it presents a danger to the wellbeing of cats. 
The Government of the Federal Republic of Germany, wrote to the 
Commission in the following terms: 
In the Annex to this letter, a report by Hickman et al. shows an 
increased presence of Heinz body formation within erythrocytes In Kittens 
fed on a diet of a feedingstuffs contai ning Propane-1,2-d i ol. From the 
results of the experi mental survey , it is mani f est I y clear that Propane-
1,2-0*10/ increases tne occurrence of Heinz bodies. This was already fcnourn 
from the data presented before author i s ing the product and it was also 
clear it could be caused by other factors in this species of animal. It 
was not, however, known that relevant physiological parameters are 
changed. However, in the survey by Hickman et al., it has been proven 
that feeding with Propane-1,2-diol significantly shortens the life-span 
of erythrocytes. This state of affairs sheds new light on the question of 
absence of danger to health in feedingstuffs for cats contai ni ng Propane-
1,2-diol because, as indicated in the survey, the shortened life-span of 
the erythrocytes could, when the animals are speci f i cal ly stressed 
(i 11 nesses , intoxication) have negative consequences on animal health. 
The Government of the Federal Republic of Germany Is therefore urging the 
Commi ss ion to put the use of Propane-1,2-dlol for cats on the agenda of 
the next meeting of the Committee of Experts on Additives which will be 
held on 19 September 1990. On this occas/on, a decision needs to be taken 
to suspend the use of the aforesaid additive until the damaging 
suspic i ons have been e I i mlnated through further experImentatI on. 
- 59 -
Opinion of the Committee 
The SCAN considered the communication received from the Federal Republic 
of Germany on the production of Heinz bodies by large doses of 1,2-
Propanediol in the food for cats and considered, provisionally that 
there was no immediate need to suspend the use of this substance. 
New references were distributed among members of the Toxicology group. 
The experts also examined a dossier that has not been examined before by 
SCAN presented by FEDIAF in 1983<2). On the basis of which admission 
was granted by Commission Directive 87/552/EEC of 17 November 1987<3) 
amending the Annexes to Council Directive 70/524/EEC concerning additives 
in feedingstuffs^4) . This dossier addressed the issues of whether Heinz 
body formation should be interpreted as a significant adverse effect in 
the cat, and justification for the level of inclusion. 
The SCAN experts agreed that this information should be examined, 
together with that provided by the Federal Republic of Germany before 
seeking to answer the questions mentioned in Annex VII and before seeking 
further data from industry. In the meantime, the declaration made at the 
71 meeting (see below), is still valid. 
"Before coming to any decision on the continued use of this substance in 
pet-food the Committee required the provision of adequate data on the 
toxicology of 1,2-Propanediol. SCAN did not consider that there was an 
immediate need to suspend the use of this substance before it had an 
opportunity to assess its safety-in-use as an ingredient of pet-food." 
(2) Fédération Européenne de l ' Industr ie des Aliments pour Animaux Familiers (F .E .D . I .A .F . ) 1983. " 1 . 2 -
Propylene Glycol (Propylene Glycol) in Soft-Moist Cat Foods. Part 1 (250 pp) and Part I I (Appendix I 
to X I , 283 pp) . Bruatei» (Belgium): Square Marie-Louise, 18. 
(3) OJ No L 336, 26.11.87. p. 34 
(4) OJ No L 270. 14.12.1970. p. 1 . 
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GUIDELINES FOR THE ASSESSMENT OF ADDITIVES IN FEEDINGSTUFFS 
Amendments proposed to modify the 
Guidelines for the Assessment of Additives in Animal Nutrition 
[Council Directive 87/153/EEC of 7 March 1987<1>]. 
to make this document also applicable for 
microorganisms and/or enzyme preparations 
intended for nutritional purposes 
Provisional Opinion Expressed July 10 1992. 
GENERAL ASPECTS 
These guidelines are intended as a guide for establishing dossiers on 
substances and preparations being submitted for authorization as 
additives in feedingstuffs. These dossiers must enable an assessment to 
be made of the additives based on the present state of knowledge and make 
it possible to ensure their compliance with the fundamental principles 
laid down for their admission, which are the subject of the provisions of 
Article 7 (2) of Council Directive 70/524/EEC of 23 November 1970 
concerning additives in feedingstuffs^2). 
Ail the studies outlined in these guidelines may be required and, if 
necessary, additional information will be requested. As a general rule, 
studies to establish the identity, conditions of use, physico-chemical 
properties, methods of determination and efficacy of the additive, and 
also its metabolism, biological and toxicological effects on target 
species must be provided. The studies necessary for the evaluation of 
risks to human health or the environment will depend essentially on the 
nature of the additive and the circumstances of its use. In this 
(r)esj&ecfcp.n¡Ms(ür.¡cot87r)i£l.o9.¡s appi i cab le . 
(2) O.J. No. L270 (14.12.70) p.1, ond O.J. No. L319 (08.12.84) p.13 
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It may not always be necessary to subject additives intended exclusively 
for pet food to be as exhaustive a programme of chronic toxicity, 
mutagenicity and carcinogenicity testing as that required for additives 
intended for feeding to livestock from which product for human 
consumption is derived. To determine chronic toxicity, studies on two 
target species or on one target species and rats for a period of one year 
will generally suffice. Mutagenesis and carcinogenesis studies can 
generally be dispensed with if the chemical composition, practical 
experience, or other considerations do not indicate the likelihood of 
changes. It is possible to dispense with the analysis of residues in pet 
animals. 
Knowledge of the metabolism of the additive in food producing stock, of 
the residues and their bioavailability is essential. In particular it 
must enable the extent of the toxi co log i cal studies to be performed on 
laboratory animals in order to assess the risks, if any, to the consumer 
to be determined. This evaluation cannot be based solely on data 
confined to determining the direct effects of the additives on laboratory 
animals. The latter do not provide specific information on the actual 
effects of residues resulting from the metabolism in the species for 
which the additive is intended. 
Any application for authorization of an additive or a new usage for an 
additive shall be supported by a dossier which should include detailed 
reports presented in the order and with the numbering proposed in these 
guidelines. Reasons must be given for the omission from the dossier of 
any data prescribed in these guidelines. Publications to which reference 
is made must be attached to it. The reports of experiments must include 
the plan and reference number of the experiment, detailed description of 
the tests, results and their analysis, and also the name, address and 
signature of the person responsible for the study. A statement from the 
person responsible for Good Laboratory Practice regarding observance of 
such practice is to be attached to the reports. 
The determination of physico-chemical, toxi co log i cal and ecotoxi co Iog i ca I 
properties shall be performed in accordance with the methods established 
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by Commission Directive 84/449/EEC of 25 April 1984 adapting to technical 
progress for the sixth time Council Directive 67/548/EEC on the 
approximation of laws, regulations and administrative provisions relating 
to the classification, packaging and labelling of dangerous 
substances^3), or with methods internationally recognized by scientific 
bodies. The use of other methods should be Justified. 
Each dossier shall contain an adequate summary. The dossiers relating 
to antibiotics, coccidiostats and other medicinal substances, growth 
promoters micro-organisms and/or enzyme preparations, must be 
accompanied by a monograph, conforming with the model provided in 
Section V, enabling the additive concerned to be identified and 
characterized in accordance with Article 8 (1) of Directive 70/524/EEC. 
The term 'additive', as used in these guidelines, refers to the active 
substances or the preparations containing active substances in the state 
in which they will be incorporated in premixtures and feedingstuffs. 
The Commission must be notified within a reasonable time by the Member 
State which forwarded the dossier to it of any modification to the 
manufacturing process or the composition of an additive, its field of 
application or its conditions of use. This could necessitate the 
submission of documentation suitable for a new assessment. These 
requirements will be especially necessary for products derived from 
micro-organisms, the genetic characteristics of which have been modified 
or which arise as natural mutants. 
(3) O.J. No. L251 (10.09.84) p.1. 
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SECTION I 
SUMMARY OF THE DATA IN THE DOSSIER 
SECTION I I 
1. Identity of the additive 
1.1 Proposed proprietary name(s) 
1.2 Type of additive according to its main function 
1.3 Qualitative and quantitative composition (active substance, other 
components, impurities) 
1.4 Physical state, particle size 
1.5 Manufacturing process including any specific processing procedures 
N.B. If the active substance is a mixture of active components, each 
clearly definable, main components must be described separately 
and the proportions of the mixture given. 
2. Specifications concerning the active substance 
2.1 Generic name, chemical name according to IUPAC nomenclature, other 
non-proprietary and generic international names and abbreviations. 
Chemical Abstracts Service Number (CAS). 
If the active substance is a micro-organism.· name and taxonomie 
description according to the international Codes of Nomenclature. 
Other internationally recognized Manuals of Systematics can also 
be used(5). 
For enzyme preparations : name according to main enzym i c 
activities as described by IUB/IUPAC, EINECS and CAS Number. 
As a general principle micro-organisms and/or enzyme preparations 
should be derived from non-pathogenic and non-toxicogenic 
microbial sources. 
(5) Such os Bergey's Monuol of Determinotive Bocterioloqy. "The Yeosts. o toxoncmic study" by Lodder. "A 
Dictionory of Fungi" by Ainsworth and Bisley or "The Genus Aspergillus" by Roper and Fennel. 
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2.2 Formula, empirical and structural, and molecular weight. 
Qualitative and quantitative composition of the main components, 
if the active substance is a fermentation product. 
For micro-organisms : name and place of culture collection, if 
possible one in an EEC collection, where the strain is deposited 
and depositing number, genetic modification and all relevant 
properties for its identification. In addition, origin, 
appropriate morphological and physiological characteristics, 
developmental stages, relevant factors that may be involved in its 
biological activity (as an additive), resistance pattern, DNA-DNA 
homology data and plasmid profile. Number of colony forming units 
(CFU) for each species . 
For enzyme preparations : the biological origin, the activities 
towards relevant chemically pure model sustratos and other 
phys i co-chem i ca I character i st i es. 
2.3. Degree of pur i ty 
For micro-organisms : genetic stability and purity of strains 
cultivated. 
For enzyme preparations : purity (checking the level of 
contaminating micro-organisms, heavy metals, absence of mycotoxins 
and antibacterial act ivi ty),and composition of the non-enzymic 
component derived from the source material. 
Qualitative and quantitative composition of the impurities. 
2.4. Relevant properties 
For chemicals: Electrostatic properties, melting point, boiling 
point, decomposition temperature, density, vapour pressure, 
solubility in water and organic solvents, mass and absorption 
spectra and any other appropriate physical properties. 
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For micro-organisms : relevant biological properties. 
For enzyme preparations: optimal pH, temperature and other 
appropriate properties. 
2.5. Manufacturing, purification processes and media used. Variation 
in the composition of the batches in the course of production. 
3. Physico-chemical, technological and biological properties of the 
additive. 
3.1. Stability (for micro-organisms loss of biological activity e.g. 
viability ) on exposure to environmental conditions such as light, 
temperature, pH, moisture and oxygen. Expiry date. 
3.2. Stability (for micro-organisms loss of biological activity, e.g. 
viability ) during the preparation of premixtures and 
feedingstuffs, in particular stability to heat, pressure and 
moisture. Possible decomposition products. 
3.3. Stability (for micro-organisms loss of biological activity, e.g. 
viability ) during the storage of premixtures and feedingstuffs 
(storage time under defined conditions). Expiry date. 
3.4. Other appropriate physico-chemical, technological or biological 
properties such as ability to obtain homogeneous mixtures in 
premixtures and feedingstuffs, dust-forming properties, and for 
micro-organisms and/or enzyme preparations, assessment of 
resistance to degradation or loss of biological activity in the 
digestive tract or by systems of simulation in vitro. 
3.5. Physico-chemical or biological incompatibi I i t ies or interactions 
(e.g. with feedingstuffs, other additives or with medicinal 
products). 
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4. Conditions of use of the additive. 
4.1. Proposed use in animal nutrition (e.g. species and category of 
animal, type of feedingstuff, period of administration and 
withdrawal period). 
4.2. Contra-ind i cat ions. 
4.3. Proposed dosing in premixture and feedingstuffs (expressed as a 
percentage of the active substance by weight or appropriate units 
of biological activity such as CFU/per gram of product for micro-
organisms or relevant activity units for enzyme preparations, for 
premixtures; and in mg/kg for feedingstuffs). 
4.4. Other known uses of the active substance or the preparation (e.g. 
in foodstuffs, human or veterinary medicine, agriculture and 
industry). For each use give the proprietary names, indications 
and contra-ind i cat ions. 
4.5. If necessary, measures for the prevention of risks and means of 
protection during manufacture and handling. 
5. Control methods. 
5.1. Description of the methods used for the determination of the 
criteria listed under items 1.3., 2.3., 2.4., 2.5., 3.1., 3.2., 
3.3., 3.4. and 4.3. 
5.2. Description of the qualitative and quantitative analytical methods 
for routine control of the additive in premixtures and 
feedingstuffs. 
5.3. Description of the qualitative and quantitative analytical methods 
for determining residues of additives in animal produce. 
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N.B. The methods specified and the results should be accompanied by 
information as to percentage recovery, specificity, limits of 
detection, possible interferences, reproducibility and to the 
sampling method used. Reference standards of the preparation and 
of the active substance must be available. 
In the case of micro-organisms state methods of detection, 
enumeration, identification and relevant markers. 
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SECTION I I I 
STUDIES CONCERNING THE EFFICACY OF THE ADDITIVE 
1. Studies concerning improvements in the characteristics of 
feedingstuffs. 
These studies concern technological additives such as 
antioxidants, preservatives, binders, emulsifiers, stabilizers and 
gelling agents, which are intended to improve or stabilise the 
characteristics of premixtures and feedingstuffs. Some micro-
organisms and/or enzyme preparations could also be considered as 
technological additives, if they improve relevant feed 
character ist ics. 
Evidence of the efficacy of the additive should be provided by 
means of appropriate criteria under the intended conditions of use 
in comparison with negative control feedingstuffs and, possibly, 
feedingstuffs containing technological additives of known 
effect iveness. 
The precise nature of the active substances, preparations, 
premises and feedingstuffs examined, the reference number of the 
batches, the concentration of the active substances in premixtures 
and feedingstuffs, the testing conditions (e.g. temperature and 
humidity) and also the dates and duration of testing, the adverse 
and negative effects which occurred during testing shall be 
specified for each experiment. 
2. Studies concerning the effects of additives on animal production. 
These studies concern zootechnical additives which have effects on 
animal production. The following studies including dose-response 
relationship, should be performed on each target species in 
comparison with negative control groups and, possibly, groups 
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receiving feedingstuffs containing additives of known 
effectiveness. If the active substance is a mixture of effective 
components, the presence of each component must be justified. 
2.1. For coccidiostats and other medicinal substances, importance 
should primarily be attached to evidence of the specific effects 
and particularly prophylactic properties (e.g. morbidity, oocyst 
count and lesion score). Information on the effect on feed 
efficiency, animal growth and marketable quantity and quality of 
the animal produce may be added. 
2.2. For other zootechnical additives (including micro-organisms and/or 
enzyme preparations) information should be provided on the effects 
on: nutritional efficiency, animal growth, animal products 
characteristics and yield, animal welfare and other parameters 
having a positive influence on animal production. 
2.3. Experimental conditions : 
The test performed must be described and the results presented 
individually in detail. The statistical evaluation and the 
methods employed should be reported. The following data must be 
provided : 
2.3.1. Species, breed, age and sex of the animals, identification 
procedure. 
2.3.2. Number of test and control groups, number of animals in each 
group. The number of animals of both sexes must be sufficient for 
statistical purposes. 
2.3.3. Concentration of the active substance using the appropriate 
recognized measure in the feedingstuffs established by a control 
analysis. Reference number of the batches. Nutritional 
composition of the diet in terms of quality and quantity. 
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2.3.4. Location of each experiment. Animal health, physiological, 
feeding and rearing conditions as usually practiced in the 
Community. Feed control and measures taken to avoid contamination 
of control groups during the experiment (particularly for micro-
organisms through self contamination by the micro-organism). 
2.3.5. Date and exact duration of test ing.Date and nature of the 
examinations performed 
2.3.6. Unfavourable effects and other incidents which occurred during the 
experiment and time of their appearance. 
3. Studies concerning the quality of animal produce. 
Studies on the organoleptic, nutritional, microbial, hygienic and 
technological qualities of edible produce from animals fed with 
feedingstuffs containing the additive. Studies of characteristics 




STUDIES CONCERNING THE SAFETY OF USE OF THE ADDITIVE 
The studies outlined in this section are intended to permit 
assessment of : 
the safety of use of the additive in the target species, 
the risks from inhalation or from cutaneous, mucosal or eye 
contact for persons likely to handle the additive as such or as 
incorporated into premixtures of feedingstuffs, 
the risks to the consumer which could result from the consumption 
of food containing residues of the additive, or its metabolites, 
the risks of pollution or survival of the environment from the 
additive itself or by products derived from the additive and 
excreted by animals, 
the risks to non-target species. 
These studies will be required in their entirety or in part 
depending on the nature of the additive and the conditions 
proposed for its use-, in the case of micro-organisms and/or 
enzyme preparations appropriate safety tests must be performed 
(including tolerance tests and a translocation test). If the 
active substance is chemically specified the knowledge of their 
metabolism in the various target species and also of the 
composition and the bioavailability of the tissue residues will be 
essential for determining the extent of studies on laboratory 
animals to assess the risks for the consumer. Furthermore, 
knowledge of the composition and of the physico-chemical and 
biological properties of the excreted residues deriving from the 
additive will be indispensable to define the extent of the studies 
necessary for assessment of the risk of pollution or survival of 
the environment. 
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1. Studies on target species 
1.1. Toxi co log i cal studies of the additive. 
Tolerance tests. 
Study of the biological, toxicological, macroscopic and 
histological effects. Determination of the safety margin between 
the maximum proposed dose-level and the level resulting in 
unfavourable effects. It may be sufficient to indicate a minimum 
or approximate value for this margin if it can be shown that the 
level resulting in unfavourable effects greatly exceeds the 
maximum proposed dose-ievel. 
1.2. Microbiological studies of the additive. 
1.2.1. If the active substance is chemically specified studies of the 
antimicrobial spectrum of action of the additive by determination 
of the Minimum Inhibitory Concentration (MIC) in various 
pathogenic and non-pathogenic Gram-negative and Gram-positive 
species of bacteria should be provided. 
1.2.2. Studies on the cross-resistance to therapeutic antibiotics by 
determination of the MIC in mutants produced, which exhibit 
chromosomal resistance to the additive. In the case of the use of 
micro-organisms which are resistant to therapeutic antibiotics a 
plasmid profile should be provided. 
1.2.3. Tests to find out whether the additive is capable of selecting 
resistance factors. These tests are to be performed under field 
conditions in the animal species for which the additive is 
primarily intended. Subsequently, it should be determined whether 
R factors which may have been found carry multiple resistance and 
are transmissible. 
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1.2.4. Tests to determine the effect of the additive 
- on the microflora of the digestive tract 
- on the colonisation of the digestive tract 
- on the shedding or excretion of pathogenic micro-
organisms. 
1.2.5. If the active substance shows an antimicrobial action field 
studies to monitor the percentage of bacteria resistant to the 
additive should be provided. These are to be carried out at major 
intervals before, during and after the use of the additive. 
1.2.6. If the additive is a micro-organism, it should be determined if it 
is resistant to antibiotics. 
1.2.7. If the additive is a genetically modified micro-organism, the 
specifically adopted guidelines should be followed . 
1.2.8. If the additive (e.g. enzyme preparations) is produced by a micro-
organism the level of contamination by the viable producer 
organism (if any) should be determined. 
1.3 Studies of the metabolism and res i dues ( 1) ( 2) 
(when the active substance is chemically specified) 
1.3.1. Study of metabolism 
- metabolic balance.- rate and extent of absorption and elimination 
of the active substance, 
- identification of the metabolic pathways and main metabolites, 
- distribution and excretion (bil Mary, urinary, faecal) of the 
metabol i tes, 
- if appropriate influence of the intestinal or ruminai 
microflora, of enterohepatic cycle, of caecotrophy, on the 
metabolism. 
(1) The studies mentioned under 1.3.1., 1.3.3., and 1.3.4. should be carried out with labelled molecules 
or other appropriate methods, in each case the choice of the method utilised should be justified. The 
labelling shoud be suitable for the purpose intended. 
(2) If the active substance is produced by fermentation, these studies should be extended to 
related substances derived from the production. 
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1.3.2. Analytical studies of the residues : qualitative and quantitative 
composition of the residues (active substance, metabolites) in the 
various animal food products at metabolic equilibrium and under 
practical conditions of use of the additive. 
1.3.3. Kinetic study of the residues (following repeated administration 
of the additive according to the proposed use) : persistence of 
the active substance and the main metabolites in the various 
organs and tissues after withdrawal of the supplemented 
feedingstuff. 
1.3.4. Study of the bioavailability of the residues in animal food 
products before and after storage and cooking (see 3.7.). 
1.3.5. Methods of monitoring : qualitative and quantitative methods of 
determination used in the studies mentioned under items 1.3.1. to 
1.3.4. with information as to percentage recovery, specificity and 
limits of detection. The methods of determination of the residues 
must be sufficiently sensitive to permit detection of residues at 
levels which are toxicologically negligible. 
2. Study on excreted residues 
(when the active substance is chemically specified) 
2.1. Nature and concentration of the residues derived from the additive 
(active substance, metabolites) in the excreta. 
2.2. Persistence (half-life value) and kinetics of elimination of these 
residues in slurries, farm yard manure and litter. 
2.3. Effects on methanogenesis. 
2.4. Degradation, persistence (half-life value) and kinetics of 
elimination in soils (contrasting soil types). 
2.5. Effects on soil fauna and microbial processes of transformation 
(e.g. decomposition of plant and animal residues). 
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2.6. Effects on terrestrial plants (e.g. seed germination, plant growth 
and plant up-take). These studies should be carried out under 
controlled conditions and field conditions, using different plant 
species. 
2.7. Solubility and stability in water of the products derived from the 
additive (active substance, metabolites). 
2.8. Effects on aquatic life. 
2.8.1. Effects on flora (e.g. Chlorella). 
2.8.2. Toxicity in non-vertebrates ( e . g . Daphnia magna). 
2.8.3. Toxicity in fish (at least two wild species found in the Community 
terr i tory). 
3. Studies on laboratory animals 
(when the active substance is a non pathogenic micro-organism 
found naturally these type of studies may not be necessary). 
These studies must be carried out with the active substance and 
its major metabolites or products, if the latter are also present 
in edible animal produce and are bioavailable. As far as possible 
attempts should be made to select laboratory animals which may be 
expected to digest and metabolize the additive in a similar way to 
man or the target species. 
Full detailed descriptions must be provided of the tests 
performed. These should cover the animal species and strains 
employed, the size and number of test and control groups, the dose 
levels administered, the composition of the diet and the results 
of feed analyses, the rearing conditions, the exact duration of 
the tests, the dates of the various examinations performed and 
mortality. Full details must be given of the macroscopic 
pathological and histopathological findings in all animals tested 
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with an indication of the time of appearance of all pathological 
lesions. All results, including statistical assessment, must be 
presented in detai I . 
3.1. Acute tox icity 
3.1.1. Acute oral toxicity studies must be carried out on two animal 
species (preferably the rat should be one). The maximum dosage 
should not be higher than 2,000 mg/kg body weight. Detailed 
observations should be reported of the biological effects observed 
during a period of at least two weeks after ingestion. 
3.1.2. Studies on acute inhalational toxicity, skin and, where necessary, 
mucous membranes irritancy and also allergenic potential must be 
performed by appropriate tests for the assessment of possible 
risks associated with the handling of the additive. 
3.2. Mutagenicity 
In order to identify active substances or their metabolites or 
products that posses mutagenic properties a selected combination 
of mutagenicity tests, based on different genetic endpoints, must 
be carried out, except if the active substance is a micro-
organism. Tests must be performed, in the presence and absence of 
a microsomal mammalian preparation for a metabolic activation. 
The following package of tests is recommended : 
(a) a test for gene mutations in a prokaryotic system, 
(b) a test for gene mutations in an in vitro eukaryotic system 
or a sex-1 inked recessive lethal test in Drosophi I a 
me Ianogaster, 
(c) a test for chromosomal damage In vitro and In vivo. 
The battery of tests suggested above does not imply, however, that 
other tests are inappropriate or that other tests, in particular 
in vivo tests, would not be acceptable as alternatives. 
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In all cases reasons for the choice of tests should be given. 
Tests must be carried out according to established validated 
procedures. Depending on the outcome of the tests and taking into 
consideration the whole toxicity profile of the substance as well 
as the intended use, additional investigations may be indicated. 
3.3. Pharmacokinetic aspects 
If the active substance is chemically specified balance studies 
and identification of metabolites must be performed using suitable 
labelled molecules or other appropriate techniques and should 
cover both single and multiple dose administration of the active 
substance over appropriate periods. Metabolism studies must also 
include investigation of the pharmacokinetics of the active 
substance and of the major metabolites. Consideration must be 
given to the differences in the way that various species 
metabolize the active substance when selecting the most relevant 
species for subsequent toxicological investigations. 
3.4. Subchronic toxicity 
These studies must be carried out in general on two animal species 
(preferably the rat should be one). The second species may in 
some instances be a target species. The test substance may be 
administered orally and a dose-response relationship must be 
established. The duration in rodents must be at least 90 days. 
In certain cases investigations extending over six months to two 
years in non-rodents (the commonly used non-rodent is the dog, 
preferably of a defined breed) may be desirable to establish the 
variation in sensitivity of different animal species to the test 
substance. 
These studies are not relevant for micro-organisms, in the case 
of enzymic preparations appropriate tests should be provided. 
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3.5. Chronic toxicity/carcinogenicity 
Chronic toxicity studies must be carried out on one species 
(preferably the rat), carcinogenicity studies preferably on two 
species of rodent. The substance must be administered orally at 
several dose levels. A combined chronic toxicity/carcinogenicity 
study with in-utero exposure is also acceptable. Experiments must 
extend for a minimum of 24 months in rats and 18 months in mice. 
If continued beyond the minimum period, the test must be 
terminated when survival in any but the highest dose level groups 
has fal len to 20%. 
Full clinical chemistry, haematological and urine examinations 
must be carried out at appropriate intervals throughout the 
experiment. Full macroscopic and histological examinations must 
be carried out on all animals dying during the test and on all 
survivors at the termination of the study. 
These studies are not relevant for micro-organisms, in the case 
of enzymic preparations appropriate tests should be provided. 
3.6. Reproductive toxicity 
Studies on reproduction must be carried out preferably on the rat. 
They must extend over at least two filial generations and may be 
combined with embryotoxici ty including teratogenic studies. All 
relevant fertility, gestation, parturition, peri- and postnatal 
parameters must be carefully observed and reported. Specific 
teratogenic studies must be carried out in at least two suitable 
species. 
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3.7. Toxicology of metabolites 
Information for the calculation of residue concentration is 
required as a basis for assessing the risk for man. 
The basis for calculation of the proposed withdrawal period must 
be made available. The studies mentioned in 1.3.4. must be 
carried out in laboratory animals. 
3.8. Other relevant studies. 
Any further special study providing additional information useful 
for the assessment of test substance may be made available (e.g. 
bioavailability, neurotoxici ty or immunotoxici ty). 
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SECTION V 
FORM OF MONOGRAPH 
1. Identity of the additive 
1.1. Type of additive according to its main function 
1.2. Qualitative and quantitative composition (active substance, other 
components, impurities) 
1.3. Physical state, particle size 
1.4. Possible specific processing. 
N.B. If the active substance is a mixture of active components, each 
clearly definable, main components must be described separately 
and the proportions of the mixture given. 
2. Specifications concerning the active substance 
2.1. Generic name, chemical name according to IUPAC nomenclature, other 
non-proprietary and generic international names and abbreviations. 
Chemical Abstracts Service Number (CAS). 
If the active substance is a micro-organism: name and taxonomie 
description according to the international Codes of Nomenclature. 
Other internationally recognized Manuals of Systematics can also 
be used C O ) . 
For enzyme preparations : name according to main enzymic 
activities as described by IUB/IUPAC, EINECS and CAS Number. 
2.2. Formula, empirical and structural, and molecular weight. 
Qualitative and quantitative composition of the main components, 
if the active substance is a fermentation product. 
For micro-organisms : name and place of culture collection, if 
possible one in an EEC collection, where the strain is deposited 
(10) Such as Bergey's Manual of Determinative Bacteriology. 'The Yeasts, a taxonomie study" by Lodder, "A 
Dictionary of Fungi" by Ainsworth and Bisley or "The Genus Aspergillus" by Raper and Fennel. 
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and depositing number, genetic modification and all relevant 
properties for its identification. 
For enzyme preparations : the biological origin, the activities 
towards relevant chemically pure model sustrates and other 
physico-chemical character ist ics. 
2.3. Degree of purity 
For micro-organisms : genetic stability and purity of strains 
cult ivated. 
For enzyme preparations : purity (checking the level of 
contaminating micro-organisms, heavy metals, absence of mycotoxins 
and antibacterial act ivi ty),and composition of the non-enzymic 
component derived from the source material. 
Qualitative and quantitative composition of the impurities 
2.4. Relevant properties 
For chemicals: Electrostatic properties, melting point, boiling 
point, decomposition temperature, density, vapour pressure, 
solubility in water and organic solvents, mass and absorption 
spectra and any other appropriate physical properties. 
For micro-organisms : relevant biological properties. 
For enzyme preparations: optimal pH, temperature and other 
appropriate properties. 
3. Physico-chemical, technological and biological properties of the 
add i t i ve. 
3.1. Stability (for micro-organisms loss of biological activity, e.g. 
viability ) on exposure to environmental conditions such as 
light, temperature, pH, moisture and oxygen. Expiry date. 
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3.2. Stability (for micro-organisms loss of biological activity, e.g. 
viability ) during the preparation of premixtures and 
feedingstuffs, in particular stability to heat, pressure and 
moisture. Possible decomposition products. 
3.3. Stability (for micro-organisms loss of biological activity, e.g. 
viability ) during the storage of premixtures and feedingstuffs 
(storage time under defined conditions). Expiry date. 
3.4. Other appropriate physico-chemical, technological or biological 
properties such as ability to obtain homogeneous mixtures in 
premixtures and feedingstuffs, dust-forming properties, and for 
micro-organisms and/or enzyme preparations, assessment of 
resistance to degradation or loss of biological activity in the 
digestive tract or by systems of simulation in vitro. 
3.5. Physico-chemical or biological incompatibilities or interactions 
(e.g. with feedingstuffs, other additives or with medicinal 
products). 
4. Control methods 
4.1. Description of the methods used for the determination of the 
criteria listed under items 1.2., 2.3., 2.4., 3.1., 3.2., 3.3. and 
3.4. of this Section. 
4.2. Description of the qualitative and quantitative analytical methods 
for determining, residues of additives in animal produce. 
4.3. If the said methods have been published, literature references may 
suffice, in this case reprints should be provided. 
5. Biological properties of the additive 
5.1. Particulars of the prophylactic effects for coccidiostats and 
other medicinal substances (e.g. morbidity, oocyst count and 
lesion score). 
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5.2. For zootechnical additives other than those listed in 
5.1.(including micro-organisms and/or enzyme preparations. 
Particulars of the effects on feed efficiency, animal growth, 
animal products characteristics and yield, animal welfare and 
other parameters having a positive influence on animal production. 
5.3. Any contra-ind i cat ions or warnings, including biological 
incompatibilities, with particulars of their justification. 
6. Details of the quantitative and qualitative residues, if any, 
found in animal produce following envisaged use of the additive. 
7. Other characteristics suitable for identification of the additive. 
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REPORTS OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION 
ACCUMULATIVE INDEX, 1979-1992 
First Series (1979) 
Catalogue No. CB-28-79-277-EN-C 
1. The use of Nitrofurans (Furazolidine, Nitrofurazone & Bifuran: 
Furazolidone + Nitrofurazone) in feedingstuffs. Opinion expressed: 5 
October 1977. p. 9. 
2. The use of Nitroimidazole derivatives in feedingstuffs^1). opinion 
expressed: 8 December 1977. p. 11. 
3. The use of macrolides (Oleandomycin, Spiramycin, Erytromycin, 
Tylosin, Lincomycin and Virginiamycin) and related products in 
feedingstuffs^2). Opinion expressed: 8 December 1977. p. 15. 
4. First report of the Scientific Committee for Animal Nutrition on the 
conditons of use of certain antibiotics in feedingstuffs (Zinc 
Bacitracin & FIavophosphoI ipo I for laying hens; Zinc Bacitracin in 
feedingstuffs for young animals). Opinion expressed: 11 October 1978. 
p. 27. 
5. Second report of the Scientific Committee for Animal Nutrition on the 
conditions of use of certain antibiotics in feedingstuffs. Use of 
Zinc Bacitracin & FIavophosphoI ipol for laying hens. Opinion 
expressed: 11 October 1978. p. 27. 
6. Report of the Scentific Committee for Animal Nutrition on the effects 
of Nitrates in feedingstuffs. Opinion expressed 19 April 1978. p. 29. 
(1) Dimetridazole (Turkey, Guinea-fowl ft Swine); Ipronidazole (Turkeys ft Guinea-Fowl). Ronidazole (Turkey 
ft Swine). 
(2) Oleandomycin (Turkeys, Other poultry, Swine), Spiramycin (Turkeys, Other poultry, Swine, Calves. Lambs 
ft Kids. Animal breed for fur), Virginiamycin (Turkeys. Other poultry. Swine. Calves. Lambs ft Kids, 
Animal breed for fur) , Erytromycin (Chicken for fattening, swine). Tylosin (Swine), Lyncomicin 
(Poultry) Oleandomycin (Poultry, Swine), Spiramycin (Poultry, Swine, Calves, Lambs ft Kids, Animal 
breed for fur) , and Virginiamycin (Poultry, Swine, Calves). 
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Second Series (1980) 
Report 6918 EN. Catalogue No CDE-NK-80-002-EN-C 
1. Report of the Scientific Committe for Animal Nutrition on the use of 
Carbadox in feedingstuffs for pigs. Opinion expressed: 6 July 1978. 
p. 7. 
2. Report of the Scientific Committee for Animal Nutrition on the use of 
Halofuglnone in feedingstuffs for Chickens. Opinion expresad: 25 
Apri I 1979. p. 11. 
3. Report of the Scientific Committee for Animal Nutrition on the use of 
Monensin Sodium and FIavophosphoI i po I in feedingstuffs for Fattening 
Cattle. Opinion expressed 26 April an 11 July 1979. p. 14. 
4. Report of the Scientific Committee for Animal Nutrition on the use of 
Avoparein in feedingstuffs for Chickens and Pigs. Opinion expressed: 
11 July 1979. p. 22. 
5. Report of the Scientific Committee for Animal Nutrition on the guide-
Lines for the assessment of additives in feedingstuffs. p. 25. 
Third Series (1981) 
Report EUR 7383 
1. Report of the Scientific Committee for Animal Nutrition on the use of 
Fumarie and Malic acids in feedingstuffs. Opinion expressed: 15 
January 1980. p. 5. 
2. Report of the Scientific Committee for Animal Nutrition on the use of 
Hydrochloric and Sulphuric acids in feedingstuffs. Opinion expressed: 
15 January 1980. p. 8. 
3. Report of the Scientific Committee for Animal Nutrition on the use of 
Polyethylene Glycol 6000 and of a Polyoxypropylene-Polyoxyethylene 
polymer in feedingstuffs. Opinion expresed: 15 January 1980. p. 12. 
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4. Report of the Scientific Committee for Animal Nutrition on the use of 
Arprinocid in feedingstuffs for chickens. Opinion expressed: 11 
December 1980. p. 15. 
5. Report of the Scientific Committee for Animal Nutrition on the use of 
inactivated cultures of selected enteropathogenic strains of E. coll 
in feedingstuffs for Piglets. Opinion expressed: 11 March 1981. 
p. 18. 
6. Report of the Scientific Committee for Animal Nutrition on Guide-
lines for the assessment of certain products to be used as sources of 
proteins in animal nutrition. Opinion expressed: 11 March 1981. 
p. 22. 
Fourth Series (1984) 
Report EUR 8769. Catalogue No CD-NK-83-OIO-EN-C 
1. Report of the Scientific Committee for Animal Nutrition on the use of 
Olaquindox in the feedingstuffs for Pigs. Opinion expressed: 8 July 
1981. p. 1. 
2. Report of the Scientific Committee for Animal Nutrition on the use of 
Copper Methionate in feedingstuffs for Pigs. Opinion expressed: 7 
October 1981. p. 6. 
3. Report of the Scientific Committee for Animal Nutrition on the use of 
Lincomycin*3) and Spiramycin in feedingstuffs. Opinion expressed: 7 
October 1981. p. 9. 
4. Report of the Scientific Committee for Animal Nutrition on the use of 
Monensin Sodium in feedingstuffs for Poultry. Opinion expressed: 10 
February 1982. p. 31. 
5. Report of the Scientific Committee for Animal Nutrition on the use of 
Robenidine in feedingstuffs for Rabbits. Opinion expressed: 10 
February 1982. p. 31. 
(3) Lincomycin (Poultry). Spiramycin (Turkeys. Other poultry, Pigs, Piglets. Calves, Lambs, Kids. Fur-
animals). 
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6. Report of the Scientific Committee for Animal Nutrition on the use of 
Salinomycin in feedingstuffs. Opinion expressed: 14 April 1982Í4). 
p. 36. 
7. Report of the Scientific Committee for Animal Nutrition on the use of 
Narasin in feedingstuffs for chickens. Opinion expressed: 14 April 
1982. p. 41. 
8. Report of the Scientific Committee for Animal Nutrition on the use of 
Nifursol in feedingstuffs for Turkeys. Opinion expressed: 14 April 
1982. p. 46. 
9. Report of the Scientific Committee for Animal Nutrition on the use of 
Nicarbazin in feedingstuffs for Poultry·^5). Opinion expressed: 14 
Apri I 1982. p. 51. 
10. Report of the Scientific Committee for Animal Nutrition on the use of 
Copper compounds in feedingstuffs^6^. Opinion expressed: 15 April 
1982. p. 56. 
11. Second report of the Scientific Committee for Animal Nutrition on the 
use of Carbadoxt7) in feedingstuffs for Pigs. Opinion expressed: 7 
July 10 1982. p. 82. 
12. Report of the Scientific Committee for Animal Nutrition on the use of 
LerbekiS) ¡n feedingstuffs for Poultry. Opinion expressed: 17 
November 1982. p. 87. 
(4) Chickens, Piglets, Pigs and Cattle. Provisional pending on reassesment. 
(5) Authorized only for fattening chickens. 
(6) Piglets, Pigs, Sehep and other animal species. 
(7) This report on carcinogenic potential of carbadox and its metabolites. First report on 2nd Series, 
p. 7. 
(8) Registered trademark of premix of metiIclorpindol and methylbenzoquate (M9Q) (100/8.35 W/W). 
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13. Report of the Scientific Committee for Animal Nutrition on the use of 
Halofuginone in feedingstuffs for Turkeys^9). Opinion expressed: 17 
November 1982. p. 94. 
14. Report of the Scientific Committee for Animal Nutrition on the use of 
Virginiamycin in feedingstuffs for Laying hensCCO. opinion 
expresed: 17 November 1982. p. 98. 
15. Report of the Scientific Committee for Animal Nutrition on the use of 
Canthaxanthin in feedingstuffs for Salmon and Trout. Opinion ex-
pressed: 14 December 1982. p. 102. 
16. Report of the Scientific Committee for Animal Nutrition on the use of 
Lasalocid Sodium in feedingstuffs for Chickens. Opinion expressed: 14 
December 1982. p. 106. 
17. Report of the Scientific Committee for Animal Nutrition on the use of 
Formaldehyde in feedingstuffs for Piglets'*11). Opinion expressed: 20 
Apri I 1983. p. 111. 
18. Report of the Scientific Committee for Animal Nutrition on the use of 
Copper compounds in feedingstuffs for Pigs^ 1 2^ 8). Opinion 
expressed: 1 June 1983. p. 116. 
19. Report of the Scientific Committee for Animal Nutritionon the use of 
Avoparein in feedingstuffs for Calves and Fattening Cattle. Opinion 
expressed: 1 June 1983. p. 120. 
(9) No objections to the uae, however unable to issue a final opinion before the results the additional 
mutagenecicity test requested. 
(10) Request additional data to justufy dose of 40 mg/kg. 
(11) Recommends precautions in handling. 
(12) Piglets and pigs, see former opinion in 4th Series, p.56 (15 Apri I 1982). 
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Fifth Series (1986) 
Report EUR 1041 EN. Catalogue No. CD-NK-86-003-EN-C 
1. Second report of the Scientific Committe for Animal Nutrition on the 
use of Monensin Sodium in feedingstuffs for Turkeys^13^. Opinion ex-
pressed: 23 November 1983. p. 1. 
2. Second report of the Scientific Committee for Animal Nutrition on the 
use of Narasin^14) in feedingstuffs for Chickens. Opinion expressed: 
8 February 1984. p. 4. 
3. Third report of the Scientific Committee for Animal Nutrition on the 
use of Halofuginone in feedingstuffs for Poultry^1^). Opinion ex-
pressed: 8 February 1984: p. 6. 
4. Second report of the Scientific Committee for Animal Nutrition on the 
use of Olaquindox in feedingstuffs for Pigs1^18). Opinion expressed: 
3rd May 1984. p. 11. 
5. Report of the Scientific Committee for Animal Nutrition on the use of 
Pancoxin^17) and Pancoxin Plus in feedingstuffs for Poultry. Opinion 
expressed: 3 May 1984. p. 13. 
6. Second report of the Scientific Committee for Animal Nutrition on the 
use of Lerbek^18) in feedingstuffs for Turkeys^19). Opinion 
expressed: 11 July 1984. p. 23. 
7. Report of the Scientific Committee for Animal Nutrition on the use of 
Zinc Bacitracin in feedingstuffs for Poultry, Pigs and Rabbits. 
Opinion expressed: 30 January 1985. p. 25. 
(13) First report in 4th Series, p.25. 
(14) First report in 4th Series, p.41. 
(15) First report in 2nd Series, p.11. Second report in 4th Series, p. 94. 
(16) First report in 4th Series, p.1. 
(17) Mixture of 18 parts amproliun, 10,8 sulphaquinoxaline, 0,9 ethopabate. 
(18) Registered trade mark of a premix containing 100 parts of meticlorpindol and 8.35 partas of 
methyIbenzoquate. 
(19) First report in 4th Series, p. 87. 
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8. Second report of the Scientific Committee for Animal Nutrition on the 
use of Nicarbazin in feedingstuffs for Fattening Chickens(20). 
Opinion expressed: 5 July 1985. p. 33. 
9. Report published jointly by the Scientific Committee for Animal 
Nutrition and the Scientific Committee for Food on the use in animal 
nutrition of protein products obtained from Candida yeasts. Opinion 
expressed: 3 May 1984. p. 35. 
10. Report published jointly by the Scientific Committee for Animal 
Nutrition and the Scientific committee for food on the use in animal 
nutrition of protein products obtained from bacteria of the 
Metilomonadaceae family(21). Opinion expressed: 23 September 1985. 
p. 51. 
Sixth Series 
Report EUR 10996. Catalogue Np_ CD-NA-12824-EN-C 
1. Report of the Scientific Committee for Animal Nutrition on the use of 
FI avophospho I i po I in feedingstuf fs^22) for Rabbits. Opinion 
expressed: 22 January 1986. p. 1. 
2. Report of the Scientific Committee for Animal Nutrition on the use of 
Nicarbazin in feedingstuffs^23) for Chickens. Opinion expressed: 8 
July 1986. p. 5. 
3. Report of the Scientific Committee for Animal Nutrition on Guidelines 
for the Assesment of Additives in Feedingstuffs^24^. p. 8. 
(20) F i rs t report in 4th Series, p .51 . 
(21) In part icular from Methylophilus cul t ivate in methanol (Pruteen). 
(22) Opinions given for laying hens (see 1st Series pp. 21 ft 27 ) ; and Fattening Catt le (see 2nd. Series 
p.14) . 
(23) Opinions given for laying hens (see 1st Series pp. 21 ft 27 ) ; ond Fattening ca t t le (see 2nd Series 
p.14) . 
(24) In regards to Ar t i c le 7 (2) of Council Directive 70/524/EEC (O.J. Ha L270. 14.12.1970 p . 1 . ft O.J. 
N» L319, 08.12.1984. p .13) . 
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Seventh Series 
Report EUR 12824 EN Catalogue No. CD-NA-12824-EN-C 
1. Report of the Scientific Committee for Animai Nutrition on the use of 
Maduramicin Ammonium in feedingstuffs for Chickens for fattening. 
Opinion expressed: 27 April 1988. p. 1. 
2. Second report of the Scientific Committee for Animal Nutrition on the 
use of Flavophosophol ipol in feedingstuffs for Rabbits'*25); Opinion 
expressed: 27 April 1988. p. 13. 
3. Report of the Scientific Committee for Animal Nutrition on the use of 
Avilamycin in feedingstuffs for Pigs. Opinion expressed: 27 April 
1988. p. 13. 
4. Report of the Scientific Committee for Animal Nutrition on the use of 
Virginiamycin in feedingstuffs for Cattle1*28). Opinion expressed: 27 
Apri I 1988. p. 21. 
5. Report of the Scientific Committee for Animal Nutrition on the use of 
Asxtaxanthin in feedingstuffs for Salmon and Trout. Opinion 
expressed: 8 March 1989. p. 29. 
6. Report of the Scientific Committee for Animal Nutrition on the use of 
Nitrovin in feedingstuffs^27). Opinion expressed: 29/30 November 
1988. p. 33. 
(25) Opinions for Laying hens (1st Series, pp.: 21 ft 27), Fattening cattle (2nd. Series, p.14) already 
given. 
(26) Opinion for utilization in Turkeys, Swine and Calves in 1st Series p.15. Opinion for use in laying 
hens in 4th Series p.98. 




Report of the Scientific Committee for Animal Nutrition on the use of 
Lasalocid Sodium in feedingstuffs for Cattle. Opinion expressed: 27 
July 1990. p. 3 
2. Report of the Scientific Committee for Animal Nutrition on 
Efrotomycin the use of in feedingstuffs for Pigs. Opinion expressed: 
27 July 1991. p. 11 
3. Report of the Scientific Committee for Animal Nutrition on the use of 
Lasalocid Sodium in feedingstuffs for Turkeys. Opinion expressed: 10 
July 1991. p. 19 
4. Report of the Scientific Committee for Animal Nutrition on the use of 
Salinomycin in feedingstuffs for Pigs. Opinion expressed: 10 July 
1991. p. 23. 
5. Report of the Scientific Committee for Animal Nutrition on the use of 
Narasin/Nicarbazin in feedingstuffs for Chickens. Provisional opinion 
expressed: 10 July 1991. p. 29. 
6. Report of the Scientific Committee for Animal Nutrition on the use of 
Diclazurii in feedingstuffs for Chickens. Opinion expressed: July 
1991. p. 39. 
7. Report of the Scientific Committee for Animal Nutrition on the use of 
Propylene-glycol (1,2-Propanediol) in feedingstuffs for Cats. Provi-
sional opinion expressed: 15 January 1991. p. 45. 
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8. Amendments proposed to modify the Guidelines for the Assessment of 
Additives in Animal Nutri t¡on<28) to make this document also 
applicable for micro-organisms and/or enzyme preparations intended 
for nutritional purposes: P.: 49 
9. Reports of the Scientific Committee for Animal Nutrition. Cumulative 
index 1974 - 1992. 
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